CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reimbursement Review Reports

Updates on CADTH drug reimbursement reviews are posted to this page. Reports are  searchable and freely available to anyone to use, download, or print for non-commercial and personal use, or private research and study, provided you do not modify them, and appropriate credit is given to CADTH.

Brand Name Generic Name Indication Recommendation Type Project Status Date Submission Received Date Recommendation Issued Proyect name
Xalkori Crizotinib Lung
First Line ALK Positive Advanced NSCLC
Notification to Implement Issued February 17, 2015 July 21, 2015 pCODR 10054
Zytiga Abiraterone acetate Genitourinary
Metastatic Castration Resistant Prostate Cancer
Notification to Implement Issued March 28, 2013 October 22, 2013 pCODR 10028
Giotrif Afatinib Lung
Advanced Non Small Cell Lung Cancer
Notification to Implement Issued June 7, 2013 May 2, 2014 pCODR 10032
Kadcyla Trastuzumab emtansine Breast
Metastatic Breast Cancer
Notification to Implement Issued March 15, 2013 January 10, 2014 pCODR 10024
Votrient Pazopanib hydrochloride Genitourinary
Metastatic Renal Cell Carcinoma
Notification to Implement Issued Resubmission Complete July 14, 2011 January 5, 2012 pCODR 10000
Treanda (in combination with rituximab) Bendamustine hydrochloride Leukemia
Chronic Lymphocytic Leukemia
Withdrawn June 27, 2014 pCODR 10040
Tykerb (in combination with Letrozole) Lapatinib Breast
Metastatic Breast Cancer
Notification to Implement Issued December 14, 2012 July 5, 2013 pCODR 10019
Arzerra Ofatumumab Leukemia
Chronic Lymphocytic Leukemia
Notification to Implement Issued April 14, 2014 January 29, 2015 pCODR 10038
Revlimid Lenalidomide Myeloma
Multiple Myeloma
Notification to Implement Issued April 5, 2013 October 22, 2013 pCODR 10029
Adcetris Brentuximab vedotin Lymphoma
Systemic Anaplastic Large Cell Lymphoma
Notification to Implement Issued March 15, 2013 December 5, 2013 pCODR 10021
Nexavar Sorafenib Endocrine
Metastatic Progressive Differentiated Thyroid Carcinoma (DTC)
Notification to Implement Issued December 19, 2014 July 16, 2015 pCODR 10049
Blincyto Blinatumomab Leukemia
Acute Lymphoblastic Leukemia
Notification to Implement Issued August 24, 2015 April 1, 2016 pCODR 10064
Jakavi Ruxolitinib Other
Polycythemia vera
Notification to Implement Issued August 27, 2015 March 3, 2016 pCODR 10065
Ninlaro Ixazomib Myeloma
Multiple Myeloma
Notification to Implement Issued December 16, 2016 June 29, 2017 pCODR 10088
Opdivo Nivolumab Head and Neck
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Notification to Implement Issued January 31, 2017 August 31, 2017 pCODR 10095
Onivyde Nanoliposomal Irinotecan Gastrointestinal
Metastatic Pancreatic Cancer
File-Closed Not Submitted pCODR 10096
Darzalex Daratumumab Myeloma
Multiple Myeloma
Notification to Implement Issued April 21, 2016 December 1, 2016 pCODR 10079
Lynparza (Resubmission) Olaparib Gynecology
Ovarian Cancer
Notification to Implement Issued March 17, 2017 September 20, 2017 pCODR 10103
Adcetris Brentuximab vedotin Lymphoma
Hodgkin Lymphoma (post-ASCT consolidation)
Withdrawn April 5, 2016 pCODR 10086
Keytruda Pembrolizumab Genitourinary
Metastatic Urothelial Carcinoma (first line)
Notification to Implement Issued February 20, 2019 October 3, 2019 pCODR 10177
Lenvima Lenvatinib Gastrointestinal
Hepatocellular Carcinoma
Notification to Implement Issued February 8, 2019 July 24, 2019 pCODR 10175
Opdivo Nivolumab Gastrointestinal
Hepatocellular Carcinoma (HCC)
Notification to Implement Issued May 8, 2018 November 29, 2018 pCODR 10134
Unituxin Dinutuximab Neurological
Neuroblastoma
Notification to Implement Issued October 1, 2018 March 26, 2019 pCODR 10154
Xalkori Crizotinib Lung
ROS1-positive advanced Non-Small Cell Lung Cancer
Notification to Implement Issued October 30, 2018 May 23, 2019 pCODR 10151
Gazyva Obinutuzumab Lymphoma
Follicular Lymphoma (previously untreated)
Notification to Implement Issued March 15, 2018 November 1, 2018 pCODR 10126
Keytruda Pembrolizumab Lung
Non-Squamous NSCLC
Notification to Implement Issued September 14, 2018 May 31, 2019 pCODR 10153
Vectibix Panitumumab Gastrointestinal
Left Sided Metastatic Colorectal Cancer
Notification to Implement Issued September 8, 2017 March 29, 2018 pCODR 10118
Blincyto Blinatumomab Leukemia
Minimal residual disease (MRD)-positive B-cell precursor acute lymphoblastic leukemia (ALL)
Withdrawn June 29, 2018 pCODR 10143
Revlimid Lenalidomide Myeloma
Multiple Myeloma
Notification to Implement Issued June 19, 2019 pCODR 10141
TBD Rituximab Lymphoma & Leukemia
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia Biosimilar
File-Closed Not Submitted pCODR 10180
Imbruvica Ibrutinib Leukemia
In combination with rituximab for previously untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL); In combination with obinutuzumab for previously untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL)
Not Filed
Rozlytrek Entrectinib Lung
ROS1-positive Non-Small Cell Lung Cancer
Under Review January 8, 2020 pCODR 10206
Bosulif (RFA) Bosutinib Leukemia
Chronic Myeloid Leukemia
Notification to Implement Issued April 8, 2019 pCODR RFA 0002
Cabometyx Cabozantinib Gastrointestinal
Hepatocellular Carcinoma
Notification to Implement Issued October 16, 2019 April 22, 2020 pCODR 10186
Kisqali Ribociclib Breast
Advanced or Metastatic Breast Cancer
Notification to Implement Issued August 26, 2019 June 4, 2020 pCODR 10194
Mylotarg Gemtuzumab Ozogamicin Leukemia
Acute Myeloid Leukemia
Notification to Implement Issued August 9, 2019 April 2, 2020 pCODR 10190
Odomzo Sonidegib Skin and Melanoma
Basal Cell Carcinoma (BCC)
Under Review June 19, 2020 pCODR 10215
Opdivo in combination with Yervoy Nivolumab in combination with Ipilimumab Lung
Non-Small Cell Lung Cancer (NSCLC)
Under Review June 23, 2020 pCODR 10218
Lonsurf Trifluridine-Tipiracil Gastrointestinal
Gastric Cancer
Notification to Implement Issued September 3, 2019 March 24, 2020 pCODR 10197
Calquence Acalabrutinib Leukemia
Chronic Lymphocytic Leukemia (CLL)
Open for Feedback on Recommendation April 7, 2020 pCODR 10211
Opdivo Nivolumab Lung
Non-Small Cell Lung Cancer
Notification to Implement Issued October 29, 2015 June 3, 2016 pCODR 10069
Votrient Pazopanib hydrochloride Genitourinary
Metastatic Renal Cell Carcinoma
Notification to Implement Issued Original Submission Complete February 20, 2013 August 29, 2013 pCODR 10022
Avastin (with capecitabine) Bevacizumab Gastrointestinal
Metastatic Colorectal Cancer
Notification to Implement Issued February 18, 2015 July 21, 2015 pCODR 10055
Halaven Eribulin Mesylate Breast
Metastatic Breast Cancer
Notification to Implement Issued February 9, 2012 August 2, 2012 pCODR 10005
Bosulif Bosutinib Leukemia
Chronic Myeloid Leukemia
Notification to Implement Issued May 30, 2014 April 21, 2015 pCODR 10039
Velcade Bortezomib Myeloma
Multiple Myeloma
Notification to Implement Issued October 29, 2012 March 25, 2013 pCODR 10016
Treanda Bendamustine hydrochloride Leukemia
Chronic lymphocytic leukemia (Relapsed/ Refractory)
Notification to Implement Issued April 24, 2012 November 29, 2012 pCODR 10011
Adcetris Brentuximab vedotin Lymphoma
Hodgkin Lymphoma
Notification to Implement Issued March 14, 2013 August 29, 2013 pCODR 10020
Perjeta Herceptin Combo Pack Pertuzumab Breast
Metastatic Breast Cancer
Notification to Implement Issued November 2, 2012 August 1, 2013 pCODR 10018
Stivarga (CRC) Regorafenib Gastrointestinal
Metastatic Colorectal Cancer
Notification to Implement Issued March 22, 2013 November 15, 2013 pCODR 10026
Xtandi Enzalutamide Genitourinary
First Line Metastatic Castration-Resistant Prostate Cancer
Notification to Implement Issued October 2, 2014 June 22, 2015 pCODR 10044
Avastin Bevacizumab Gynecology
Cervical Cancer
Notification to Implement Issued October 27, 2014 March 23, 2015 pCODR 10045
Vectibix Panitumumab Gastrointestinal
Metastatic Colorectal Cancer
Notification to Implement Issued April 15, 2015 December 3, 2015 pCODR 10060
Imbruvica Ibrutinib Lymphoma
Mantle Cell Lymphoma
Notification to Implement Issued January 29, 2016 July 19, 2016 pCODR 10073
Zydelig Idelalisib Lymphoma
Follicular Lymphoma
Notification to Implement Issued April 12, 2016 September 29, 2016 pCODR 10075
Afinitor Everolimus Endocrine
Neuroendocrine tumours of Gastrointestinal or Lung origin
Notification to Implement Issued May 30, 2016 December 1, 2016 pCODR 10083
Bavencio Avelumab Skin & Melanoma
metastatic Merkel Cell Carcinoma
Notification to Implement Issued October 10, 2017 March 21, 2018 pCODR 10124
Kyprolis Carfilzomib Myeloma
Multiple Myeloma (relapsed)
Notification to Implement Issued September 9, 2016 March 30, 2017 pCODR 10084
Tafinlar & Mekinist in combo Dabrafenib & Trametinib in combo Lung
Non-Small Cell Lung Cancer
Notification to Implement Issued March 31, 2017 November 2, 2017 pCODR 10106
Erbitux Cetuximab Gastrointestinal
Left Sided Metastatic Colorectal Cancer
File-Closed Not Submitted pCODR 10128
Ninlaro Ixazomib Myeloma
Multiple Myeloma (2nd-beyond)
Notification to Implement Issued November 30, 2018 July 5, 2019 pCODR 10164
Keytruda Pembrolizumab Skin & Melanoma
Melanoma Adjuvant Treatment
Notification to Implement Issued December 13, 2018 August 1, 2019 pCODR 10168
Ogivri Trastuzumab Breast / Gastrointestinal
Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar
Withdrawn December 18, 2018 pCODR 10169
Perjeta-Herceptin Combo Pack Pertuzumab-Trastuzumab Combo Pack Breast
Early Breast Cancer
Notification to Implement Issued April 9, 2018 November 29, 2018 pCODR 10127
Idhifa Enasidenib Leukemia
Acute Myeloid Leukemia (AML)
Notification to Implement Issued April 5, 2019 October 31, 2019 pCODR 10144
Tafinlar & Mekinist in combo Dabrafenib & Trametinib in combo Skin & Melanoma
Melanoma Adjuvant Therapy
Notification to Implement Issued September 21, 2018 May 3, 2019 pCODR 10152
Ibrance (with Faslodex) Palbociclib (with Fulvestrant) Breast
Advanced or Metastatic Breast Cancer
Notification to Implement Issued September 28, 2018 May 3, 2019 pCODR 10150
Vizimpro Dacomitinib Lung
Non-Small Cell Lung Cancer
Notification to Implement Issued September 19, 2018 May 31, 2019 pCODR 10129
Lynparza Olaparib Gynecology
Ovarian Cancer
Notification to Implement Issued April 18, 2019 December 5, 2019 pCODR 10174
Adcetris Brentuximab Vedotin Lymphoma
Peripheral T-cell Lymphoma (PTCL)
Notification to Implement Issued October 8, 2019 June 4, 2020 pCODR 10199
Xospata Gilteritinib Leukemia
Acute Myeloid Leukemia (AML)
Notification to Implement Issued October 28, 2019 May 20, 2020 pCODR 10202
Lutathera Lutetium Lu 177 dotatate Gastrointestinal
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Notification to Implement Issued July 30, 2018 August 1, 2019 pCODR 10142
Zytiga (Resubmission) Abiraterone Genitourinary
Prostate Cancer
Suspended July 29, 2019 pCODR 10201
Nubeqa Darolutamide Genitourinary
Non-Metastatic Castration Resistant Prostate Cancer
Notification to Implement Issued August 27, 2019 April 22, 2020 pCODR 10196
Oncaspar Pegaspargase Leukemia
Adult Acute Lymphocytic Leukemia (ALL)
Not Filed
Atriance Nelarabine Leukemia
Acute Lymphoblastic Leukemia
File-Closed Not Submitted pCODR 10170
Zejula Niraparib Gynecology
Ovarian Cancer
Notification to Implement Issued February 7, 2020 September 3, 2020 pCODR 10203
Alecensaro Alectinib Lung
Locally advanced or metastatic non-small cell lung cancer (second line)
Notification to Implement Issued August 18, 2017 March 29, 2018 pCODR 10114
Daurismo Glasdegib Leukemia
Acute Myeloid Leukemia (AML)
Open for Feedback on Recommendation May 6, 2020 pCODR 10207
Erbitux Cetuximab Gastrointestinal
Metastatic Colorectal Cancer
Notification to Implement Issued June 10, 2013 January 10, 2014 pCODR 10031
Afinitor Everolimus Gastrointestinal
Pancreatic neuroendocrine tumours
Notification to Implement Issued February 27, 2012 August 30, 2012 pCODR 10007
Avastin Bevacizumab Gynecology
Ovarian Cancer
Notification to Implement Issued November 28, 2014 June 4, 2015 pCODR 10047
Xtandi Enzalutamide Genitourinary
Metastatic Castration Resistant Prostate Cancer
Notification to Implement Issued March 4, 2013 July 23, 2013 pCODR 10023
Inlyta Axitinib Genitourinary
Metastatic Renal Cell Carcinoma
Notification to Implement Issued August 16, 2012 March 7, 2013 pCODR 10013
Perjeta or Perjeta-Herceptin Combo Pack Pertuzumab Breast
Neoadjuvant Breast Cancer
Notification to Implement Issued December 19, 2014 July 16, 2015 pCODR 10050
Imbruvica Ibrutinib Leukemia
Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (previously treated)
Notification to Implement Issued August 15, 2014 March 5, 2015 pCODR 10043
Sutent Sunitinib malate Gastrointestinal
Pancreatic neuroendocrine tumours
Notification to Implement Issued November 7, 2011 May 3, 2012 pCODR 10004
Treanda Bendamustine hydrochloride Leukemia
Chronic lymphocytic leukemia (First Line)
Notification to Implement Issued April 24, 2012 February 19, 2013 pCODR 10011
Votrient Pazopanib Hydrochloride Sarcoma
Soft Tissue Sarcoma (STS)
Notification to Implement Issued June 4, 2012 November 29, 2012 pCODR 10009
Stivarga (GIST) Regorafenib Other
Gastrointestinal Stromal Tumours
Notification to Implement Issued October 11, 2013 May 2, 2014 pCODR 10034
Verzenio Abemaciclib Breast
Advanced or metastatic breast cancer
Notification to Implement Issued December 3, 2018 July 5, 2019 pCODR 10161
Lonsurf Trifluridine and Tipiracil Gastrointestinal
Metastatic Colorectal Cancer
Notification to Implement Issued November 6, 2017 July 6, 2018 pCODR 10122
Alecensaro Alectinib Lung
Non-Small Cell Lung Cancer (first line)
Notification to Implement Issued January 15, 2018 July 25, 2018 pCODR 10125
Rydapt Midostaurin Leukemia
Acute Myeloid Leukemia
Notification to Implement Issued June 12, 2017 December 19, 2017 pCODR 10108
Stivarga Regorafenib Gastrointestinal
Unresectable Hepatocellular Carcinoma (HCC)
Notification to Implement Issued October 12, 2017 April 18, 2018 pCODR 10119
Folotyn Pralatrexate Lymphoma
Peripheral T-Cell Lymphoma (PTCL)
Notification to Implement Issued June 1, 2018 April 4, 2019 pCODR 10138
Lenvima Lenvatinib Genitourinary
Renal Cell Carcinoma (RCC)
Notification to Implement Issued June 8, 2018 January 4, 2019 pCODR 10140
Zykadia Ceritinib Lung
Metastatic Non-Small Cell Lung Cancer
Notification to Implement Issued June 5, 2015 December 3, 2015 pCODR 10062
Opdivo & Yervoy in combo Nivolumab & Ipilimumab in combo Skin and Melanoma
Metastatic Melanoma
Notification to Implement Issued November 30, 2016 November 30, 2017 pCODR 10098
Gazyva Obinutuzumab Lymphoma
Follicular Lymphoma
Notification to Implement Issued November 4, 2016 June 2, 2017 pCODR 10091
Ibrance Resubmission Palbociclib Breast
Advanced Breast Cancer
Notification to Implement Issued June 10, 2016 November 21, 2016 pCODR 10093
Opdivo Nivolumab Skin and Melanoma
Metastatic Melanoma
Notification to Implement Issued August 13, 2015 April 1, 2016 pCODR 10063
Tagrisso Osimertinib Lung
Non-Small Cell Lung Cancer
Notification to Implement Issued April 1, 2016 May 4, 2017 pCODR 10076
Opdivo Nivolumab Genitourinary
Metastatic Renal Cell Carcinoma
Notification to Implement Issued February 24, 2016 September 1, 2016 pCODR 10074
Blincyto Blinatumomab Leukemia
Pediatric Acute Lymphoblastic Leukemia (ALL)
Notification to Implement Issued February 24, 2017 August 23, 2017 pCODR 10099
Keytruda Pembrolizumab Lymphoma
classical Hodgkin Lymphoma (cHL)
Notification to Implement Issued July 7, 2017 January 5, 2018 pCODR 10109
Inlyta (RFA) Axitinib Genitourinary
Metastatic Renal Cell Carcinoma
Notification to Implement Issued April 18, 2017 pCODR RFA 0001
Kisqali Ribociclib Breast
Advanced or Metastatic Breast Cancer
Notification to Implement Issued October 17, 2017 April 18, 2018 pCODR 10112
Venclexta Venetoclax Obinutuzumab Leukemia
Chronic Lymphocytic Leukemia (CLL)
Open for Feedback on Recommendation April 17, 2020 pCODR 10212
Unituxin Dinutuximab Neurological
Neuroblastoma (pediatric)
Pending pCODR 10222
TBD Trastuzumab Breast & Gastrointestinal
Breast and Gastric Cancer Biosimilar
File-Closed Not Submitted pCODR 10160
Zytiga Abiraterone Genitourinary
Prostate Cancer
Withdrawn February 25, 2019 pCODR 10166
Darzalex Daratumumab Myeloma
Multiple Myeloma (newly diagnosed)
Notification to Implement Issued January 4, 2019 August 29, 2019 pCODR 10148
Kadcyla Trastuzumab Emtansine Breast
Early Breast Cancer (EBC)
Notification to Implement Issued July 2, 2019 January 22, 2020 pCODR 10182
Demylocan Decitabine Other
Myelodysplastic Syndromes
Not Filed
Polivy Polatuzumab Vedotin Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Under Review September 29, 2020 pCODR 10227
Alunbrig Brigatinib Lung
Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer
Under Review September 30, 2020 pCODR 10230
Rydapt Midostaurin Other
Systemic Mastocytosis
Notification to Implement Issued August 13, 2019 April 2, 2020 pCODR 10193
Imbruvica Ibrutinib Lymphoma
In combination with rituximab for Waldenstrom's Macroglobulinemia
Not Filed
Darzalex Daratumumab Multiple Myeloma
Myeloma
Notification to Implement Issued July 17, 2019 March 5, 2020 pCODR 10189
Tecentriq Atezolizumab Lung
Small Cell Lung Cancer (SCLC)
Notification to Implement Issued March 4, 2019 January 30, 2020 pCODR 10156
Tecentriq & Avastin Atezolizumab & Bevacizumab Lung
Non-Squamous Non-Small Cell Lung Cancer
Notification to Implement Issued November 18, 2019 July 3, 2020 pCODR 10155
Truxima Rituximab Lymphoma & Leukemia
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia Biosimilar
File-Closed Not Submitted pCODR 10184
Keytruda Pembrolizumab Gynecology
Adult patients with unresectable or metastatic microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) endometrial cancer whose tumours have progressed following prior therapy and who have no satisfactory alternative treatment options, as monotherapy.
Not Filed
Tafinlar & Mekinist in combo Dabrafenib & Trametinib in combo Skin and Melanoma
Metastatic Melanoma
Notification to Implement Issued February 13, 2015 July 21, 2015 pCODR 10053
Xalkori Crizotinib Lung
Advanced Non-Small Cell Lung Cancer
Notification to Implement Issued Original Submission Complete March 26, 2012 October 4, 2012 pCODR 10008
Treanda Bendamustine hydrochloride Lymphoma
Non-Hodgkin lymphoma (NHL)
Notification to Implement Issued April 24, 2012 November 29, 2012 pCODR 10010
Zaltrap Aflibercept Gastrointestinal
Metastatic Colorectal Cancer
Notification to Implement Issued November 26, 2013 September 5, 2014 pCODR 10035
Yervoy Ipilimumab Skin and Melanoma
Advanced Melanoma
Notification to Implement Issued December 1, 2011 April 18, 2012 pCODR 10003
Afinitor Everolimus Breast
Advanced Breast Cancer
Notification to Implement Issued September 5, 2012 March 25, 2013
Stivarga Resubmission (CRC) Regorafenib Gastrointestinal
Metastatic Colorectal Cancer
Notification to Implement Issued December 19, 2014 July 16, 2015 pCODR 10046
Erivedge Vismodegib Skin and Melanoma
Advanced Basal Cell Carcinoma
Notification to Implement Issued June 14, 2013 January 10, 2014
Sylvant Siltuximab Lymphoma
Multicentric Castleman's Disease (MCD)
Notification to Implement Issued January 30, 2015 June 22, 2015 pCODR 10052
Pomalyst Pomalidomide Myeloma
Multiple Myeloma
Notification to Implement Issued January 13, 2014 July 31, 2014 pCODR 10036
Imbruvica Ibrutinib Leukemia
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (previously untreated)
Notification to Implement Issued April 20, 2016 November 3, 2016 pCODR 10085
Lenvima Lenvatinib Endocrine
Differentiated Thyroid Cancer
Notification to Implement Issued April 18, 2016 September 20, 2016 pCODR 10080
Imbruvica Ibrutinib Lymphoma
Waldenstrom's Macroglobulinemia
Pending April 21, 2016 November 3, 2016 pCODR 10082
Kyprolis (with lenalidomide) Carfilzomib (with lenalidomide) Myeloma
Multiple Myeloma
Notification to Implement Issued December 11, 2015 June 21, 2016 pCODR 10067
Yondelis Trabectedin Sarcoma
Metastatic Liposarcoma or Leiomyosarcoma
Notification to Implement Issued December 22, 2015 August 5, 2016 pCODR 10071
Cotellic Cobimetinib Skin and Melanoma
Metastatic Melanoma
Notification to Implement Issued December 11, 2015 June 30, 2016 pCODR 10070
Venclexta Venetoclax Leukemia
Chronic Lymphocytic Leukemia (with 17p deletion)
Withdrawn July 8, 2016 pCODR 10087
Tecentriq Atezolizumab Lung
Non-Small Cell Lung Cancer
Notification to Implement Issued December 15, 2017 June 20, 2018 pCODR 10115
Opdivo Nivolumab Lymphoma
classical Hodgkin Lymphoma after failure of ASCT
Notification to Implement Issued September 29, 2017 May 3, 2018 pCODR 10120
Lartruvo Olaratumab Sarcoma
Advanced Soft Tissue Sarcoma (STS)
Notification to Implement Issued October 26, 2017 April 18, 2018 pCODR 10111
Darzalex Daratumumab Myeloma
Multiple Myeloma (second-line or beyond)
Notification to Implement Issued March 3, 2017 October 5, 2017 pCODR 10104
Keytruda Pembrolizumab Skin and Melanoma
Metastatic Melanoma
Notification to Implement Issued April 16, 2015 November 16, 2015 pCODR 10058
Caprelsa Vandetanib Endocrine
Medullary Thyroid Cancer
Notification to Implement Issued August 15, 2016 March 30, 2017 pCODR 10090
Zykadia (Resubmission) Ceritinib Lung
Non-Small Cell Lung Cancer
Notification to Implement Issued October 19, 2016 March 21, 2017 pCODR 10094
Opdivo in combination with Yervoy Nivolumab in combination with Ipilimumab Genitourinary
Renal Cell Carcinoma
Notification to Implement Issued April 26, 2018 November 1, 2018 pCODR 10132
Erleada Apalutamide Genitourinary
Castrate Resistant Prostate Cancer
Notification to Implement Issued April 16, 2018 November 1, 2018 pCODR 10133
Opdivo Nivolumab Skin & Melanoma
Melanoma Adjuvant Therapy
Notification to Implement Issued August 27, 2018 March 7, 2019 pCODR 10147
Venclexta in combo Rituximab Venetoclax Leukemia
Chronic Lymphocytic Leukemia (CLL)
Notification to Implement Issued October 24, 2018 May 31, 2019 pCODR 10162
Imfinzi Durvalumab Lung
Non-Small Cell Lung Cancer
Notification to Implement Issued September 21, 2018 May 3, 2019 pCODR 10131
Kisqali Ribociclib with Fulvestrant Breast
Advanced or Metastatic Breast Cancer
Notification to Implement Issued August 26, 2019 April 22, 2020 pCODR 10195
Tecentriq Atezolizumab Breast
Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)
Withdrawn October 2, 2019 pCODR 10171
TBD Bevacizumab Gastrointestinal / Lung
Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer Biosimilar
File Closed March 14, 2019 pCODR 10178
Zevalin Ibritumomab tiuxetan Lymphoma
Non-Hodgkin’s Lymphoma (NHL)
Not Filed
Keytruda Pembrolizumab Lung
Squamous NSCLC
Notification to Implement Issued February 8, 2019 January 3, 2020 pCODR 10176
Vitrakvi Larotrectinib Other
Neurotrophic Tyrosine Receptor Kinase
Open for Input on Submission pCODR 10221
Vitrakvi Larotrectinib Other
Neurotrophic Tyrosine Receptor Kinase (NTRK) Locally Advanced or Metastatic Solid Tumours
Notification to Implement Issued February 25, 2019 October 31, 2019 pCODR 10159
Lorbrena Lorlatinib Lung
Non-Small Cell Lung Cancer (NSCLC)
Notification to Implement Issued June 11, 2019 January 30, 2020 pCODR 10183
Inrebic Fedratinib Other
Myelofibrosis
Pending pCODR 10205
Tecentriq & Avastin Atezolizumab & Bevacizumab Gastrointestinal
Hepatocellular Carcinoma (HCC)
Open for Feedback on Recommendation May 21, 2020 pCODR 10217
Istodax Romidepsin Lymphoma
Peripheral T-Cell Lymphoma
Notification to Implement Issued December 1, 2014 May 19, 2015 pCODR 10048
Adcetris Brentuximab Vedotin Lymphoma
Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine, and dacarbazine (AVD)
Under Review April 2, 2020 pCODR 10214
Keytruda Pembrolizumab Genitourinary
Metastatic Urothelial Carcinoma
Notification to Implement Issued July 24, 2017 March 2, 2018 pCODR 10117
Calquence Acalabrutinib Leukemia
Chronic Lymphocytic Leukemia (CLL) (previously untreated)
Open for Feedback on Recommendation April 7, 2020 pCODR 10210
Jakavi Ruxolitinib Other
Myelofibrosis
Notification to Implement Issued June 25, 2012 January 14, 2013 pCODR 10012
Mekinist Trametinib Skin and Melanoma
Metastatic Melanoma
Notification to Implement Issued May 6, 2013 October 22, 2013 pCODR 10030
Gazyva Obinutuzumab Leukemia
Chronic Lymphocytic Leukemia
Notification to Implement Issued August 11, 2014 January 27, 2015 pCODR 10041
Alimta Pemetrexed Lung
Advanced Non-Squamous Non Small Cell Lung Cancer
Notification to Implement Issued May 31, 2013 November 19, 2013 pCODR 10027
Proleukin Aldesleukin (IL-2) Skin and Melanoma
In-transit Melanoma
Notification to Implement Issued January 30, 2015 June 22, 2015 pCODR 10051
Xalkori Crizotinib Lung
Advanced Non-Small Cell Lung Cancer
Notification to Implement Issued Original Submission Complete October 23, 2012 May 2, 2013
Trisenox Arsenic Trioxide Leukemia
Acute Promyelocytic Leukemia
Notification to Implement Issued August 30, 2013 February 18, 2014 pCODR 10033
Tafinlar Dabrafenib Skin and Melanoma
Metastatic Melanoma
Notification to Implement Issued March 18, 2013 December 5, 2013 pCODR 10025
Zelboraf Vemurafenib Skin and Melanoma
Advanced Melanoma
Notification to Implement Issued December 6, 2011 June 1, 2012 pCODR 10006
Yervoy Ipilimumab Skin and Melanoma
First Line Advanced Melanoma
Notification to Implement Issued August 15, 2014 December 22, 2014 pCODR 10042
Zydelig Idelalisib Leukemia
Chronic Lymphocytic Leukemia
Notification to Implement Issued April 7, 2015 August 18, 2015 pCODR 10057
Cyramza Ramucirumab Gastrointestinal
Metastatic Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma
Notification to Implement Issued April 15, 2015 October 29, 2015 pCODR 10059
Iclusig Ponatinib Leukemia
Chronic Myeloid Leukemia/ Acute Lymphoblastic Leukemia
Notification to Implement Issued March 13, 2015 October 1, 2015 pCODR 10056
Revlimid Lenalidomide Myeloma
Multiple Myeloma (newly diagnosed)
Notification to Implement Issued May 4, 2015 December 3, 2015 pCODR 10061
Cyramza Ramucirumab Lung
Non-Small Cell Lung Cancer
File-Closed Not Submitted pCODR 10078
Alecensaro Alectinib Lung
Non-Small Cell Lung Cancer (with CNS metastases)
Notification to Implement Issued October 3, 2016 May 4, 2017 pCODR 10092
Avastin Bevacizumab Lung
Malignant Pleural Mesothelioma
Withdrawn December 16, 2016 pCODR 10100
Blincyto (Resubmission) Blinatumomab Leukemia
Adult Acute Lymphoblastic Leukemia (ALL)
Notification to Implement Issued February 24, 2017 August 31, 2017 pCODR 10097
Onivyde Irinotecan Liposome Gastrointestinal
Metastatic Pancreatic Cancer
Notification to Implement Issued April 27, 2017 January 5, 2018 pCODR 10107
Keytruda Pembrolizumab Lung
Non-Small Cell Lung Cancer (Second Line or Beyond)
Notification to Implement Issued April 21, 2016 November 3, 2016 pCODR 10077
Rituxan Rituximab Leukemia
Acute Lymphoblastic Leukemia
Notification to Implement Issued February 13, 2017 August 31, 2017 pCODR 10102
Lynparza Olaparib Gynecology
Ovarian Cancer
Notification to Implement Issued April 1, 2016 September 29, 2016 pCODR 10081
TBD Entrectinib Other
Neurotrophic Tyrosine Receptor Kinase (NTRK) Fusion-Positive Solid Tumours
Withdrawn July 29, 2019 pCODR 10157
Keytruda Pembrolizumab Genitourinary
Renal Cell Carcinoma
Notification to Implement Issued August 2, 2019 April 2, 2020 pCODR 10185
Adcetris Brentuximab Vedotin Lymphoma
Hodgkin’s Lymphoma at high risk of relapse or progression post-ASCT
Notification to Implement Issued August 10, 2017 February 21, 2018 pCODR 10116
Mvasi Bevacizumab Gastrointestinal / Lung
Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar
Final Biosimilar Dossier Issued October 3, 2018 pCODR 10158
Alunbrig Brigatinib Lung
Non-Small Cell Lung Cancer (NSCLC)
Notification to Implement Issued December 5, 2018 August 1, 2019 pCODR 10167
Xtandi Enzalutamide Genitourinary
Non-metastatic castration-resistant prostate cancer
Notification to Implement Issued September 24, 2018 March 26, 2019 pCODR 10149
Cabometyx Cabozantinib Genitourinary
Renal Cell Carcinoma
Notification to Implement Issued September 17, 2018 February 20, 2019 pCODR 10163
Tagrisso Osimertinib Lung
Non-Small Cell Lung Cancer (first line)
Notification to Implement Issued May 16, 2018 January 4, 2019 pCODR 10137
Venclexta Venetoclax Leukemia
Chronic Lymphocytic Leukemia
Notification to Implement Issued July 10, 2017 March 2, 2018 pCODR 10105
TBD Cabozantinib Genitourinary
Renal Cell Carcinoma (RCC)
Withdrawn October 6, 2017 pCODR 10123
Nerlynx Neratinib Breast
Hormone Receptor-Positive Breast Cancer
Notification to Implement Issued April 18, 2019 December 5, 2019 pCODR 10172
Faslodex Fulvestrant Breast
Locally Advanced or Metastatic Breast Cancer
Notification to Implement Issued July 17, 2017 February 1, 2018 pCODR 10110
Besponsa Inotuzumab Ozogamicin Leukemia
Acute Lymphoblastic Leukemia (ALL)
Notification to Implement Issued November 13, 2017 July 6, 2018 pCODR 10121
Avastin Bevacizumab Gynecology
Platinum-Resistant Ovarian Cancer
Notification to Implement Issued October 29, 2015 May 5, 2016 pCODR 10066
Ibrance Palbociclib Breast
Advanced Breast Cancer
Suspended November 11, 2015 pCODR 10068
Beleodaq Belinostat Lymphoma
Peripheral T-Cell Lymphoma (PTCL)
Withdrawn June 29, 2018 pCODR 10139
Libtayo Cemiplimab Skin & Melanoma
Cutaneous Squamous Cell Carcinoma
Notification to Implement Issued July 9, 2019 January 22, 2020 pCODR 10187
Lonsurf Trifluridine and Tipiracil Gastrointestinal
Metastatic Colorectal Cancer
Notification to Implement Issued January 21, 2019 August 29, 2019 pCODR 10173
Pomalyst Pomalidomide Myeloma
Multiple Myeloma (second-line or beyond)
Notification to Implement Issued March 15, 2019 September 18, 2019 pCODR 10165
Adcetris (Resubmission) Brentuximab Vedotin Lymphoma
Hodgkin Lymphoma
Notification to Implement Issued August 27, 2018 March 7, 2019 pCODR 10145
Blincyto Blinatumomab Leukemia
Philadelphia chromosome positive (Ph+) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL)
Notification to Implement Issued August 31, 2018 April 4, 2019 pCODR 10146
Xtandi Enzalutamide Genitourinary
Metastatic Castration Sensitive Prostate Cancer (mCSPC)
Notification to Implement Issued February 24, 2020 September 23, 2020 pCODR 10209
Keytruda Pembrolizumab Head and Neck
Head and Neck Squamous Cell Carcinoma (HNSCC)
Under Review May 1, 2020 pCODR 10216
Keytruda Pembrolizumab Gastrointestinal
Adult patients with unresectable or metastatic microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer whose tumours have progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, as monotherapy.
Not Filed
Adcetris Brentuximab Vedotin Lymphoma
Primary Cutaneous Anaplastic Large Cell Lymphoma or CD30-Expressing Mycosis Fungoides
Under Review March 30, 2020 pCODR 10213
Lynparza Olaparib Breast
Treatment of adult patients with deleterious or suspected deleterious germline BRCAmutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting.
Not Filed
Blincyto Blinatumomab Leukemia
Minimal Residual Disease (MRD)-Positive B-Cell Precursor Acute Lymphoblastic Leukemia (BCP ALL)
Final Recommendation Posted January 20, 2020 October 29, 2020 pCODR 10204
Abraxane Nab-paclitaxel Gastrointestinal
Metastatic Pancreatic Cancer
Notification to Implement Issued February 14, 2014 September 23, 2014 pCODR 10037
Sarclisa Isatuximab Myeloma
Multiple Myeloma
Under Review August 17, 2020 pCODR 10220
Zejula Niraparib Gynecology
Ovarian Cancer
Under Review September 21, 2020 pCODR 10224
Lynparza Olaparib Genitourinary
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Under Review September 22, 2020 pCODR 10223
Tafinlar and Mekinist Dabrafenib and Trametinib Lung
Non-Small Cell Lung Cancer (NSCLC) BRAF V600 mutation
Under Review October 1, 2020 pCODR 10226
Bavencio Avelumab Genitourinary
Urothelial Carcinoma (UC)
Under Review September 18, 2020 pCODR 10225
Erleada Apalutamide Genitourinary
Metastatic Castration-Sensitive Prostate Cancer
Notification to Implement Issued October 15, 2019 April 22, 2020 pCODR 10200
Keytruda Pembrolizumab Lung
Non-Small Cell Lung Carcinoma (First Line)
Notification to Implement Issued December 12, 2016 August 23, 2017 pCODR 10101
Inqovi Decitabine-Cedazuridine Leukemia
Myelodysplastic Syndromes (MDS)
Under Review October 9, 2020 pCODR 10228
Gynazole.1 Butoconazole nitrate Vaginal infection Do not list Complete June 30, 2004 January 26, 2005 S0017
NovoMix 30 Insulin aspart/insulin aspart protamine Diabetes mellitus Do not list Complete October 13, 2005 April 26, 2006 S0041
Fosavance 70/5600 Alendronate sodium / cholecalciferol Osteoporosis List in a similar manner to other drugs in class Complete December 18, 2008 June 17, 2009 S0153
Abilify Aripiprazole Schizophrenia Do not list Complete November 6, 2009 April 27, 2010 S0183
Abilify Aripiprazole Depression, Major Depressive Disorder (MDD) Do not list Complete October 1, 2013 October 22, 2014 SR0354
Abilify Aripiprazole Schizophrenia and Related Psychotic Disorders List with clinical criteria and/or conditions Complete March 29, 2011 July 18, 2011 S0226
Abilify Maintena Aripiprazole Schizophrenia List with criteria/condition Complete January 6, 2014 December 19, 2014 SR0366-000
Abstral Fentanyl citrate Pain, Cancer (breakthrough) Do not list Complete June 30, 2011 December 16, 2011 S0240
Aclasta Zoledronic acid Osteoporosis (postmenopausal women) List with clinical criteria and/or conditions Complete July 20, 2011 November 16, 2011 S0242
Aclasta Zoledronic acid Osteoporosis, postmenopausal women List with clinical criteria and/or conditions Complete November 29, 2007 June 25, 2008 S0114
Actemra Tocilizumab Arthritis, juvenile idiopathic List with clinical criteria and/or conditions Complete January 30, 2012 July 19, 2012 S0267
Actemra Tocilizumab Polyarticular juvenile idiopathic arthritis List with criteria/condition Complete July 29, 2013 March 19, 2014 SR0343
Actemra Tocilizumab Arthritis, Rheumatoid List with criteria/condition Complete March 3, 2014 February 19, 2015 SR0374-000
Actemra Tocilizumab Arthritis, Rheumatoid List with clinical criteria and/or conditions Complete May 27, 2010 November 17, 2010 S0201
Actemra tocilizumab Giant cell arteritis (GCA) Reimburse with clinical criteria and/or conditions Complete September 25, 2017 March 27, 2018 SR0534-000
Actikerall Fluorouracil and Salicylic Acid Hyperkeratotic actinic keratosis Reimburse with clinical criteria and/or conditions Complete August 31, 2016 March 22, 2017 SR0498
Adcirca Tadalafil Pulmonary arterial hypertension List with clinical criteria and/or conditions Complete February 5, 2010 July 15, 2010 S0197
Adderall XR Mixed amphetamine salts Attention deficit hyperactivity disorder Withdrawn December 15, 2004 S0027
Adderall XR Mixed amphetamine salts Attention deficit hyperactivity disorder Do not list Complete April 13, 2004 November 24, 2004 S0010
Adderall XR Mixed amphetamine salts Attention deficit hyperactivity disorder, Adult Do not list Complete November 29, 2007 June 25, 2008 S0116
Adempas Riociguat Pulmonary hypertension, chronic thromboembolic List with criteria/condition Complete September 30, 2013 July 17, 2014 SR0353
Adempas Riociguat Pulmonary arterial hypertension (WHO group 1) List with clinical criteria and/or conditions Complete June 25, 2015 December 17, 2015 SR0438-000
Adlyxine lixisenatide Diabetes mellitus, Type 2 Reimburse with clinical criteria and/or conditions Complete May 29, 2017 November 23, 2017 SR0520-000
Admelog Insulin lispro Diabetes mellitus, Type 1 & 2 Cancelled SE0543-000
Advicor Niacin/lovastatin Hypercholesterolemia and mixed dyslipidemia List Complete October 18, 2005 April 26, 2006 S0042
Aermony RespiClick fluticasone propionate Asthma Reimburse with clinical criteria and/or conditions Complete October 4, 2017 December 19, 2018 SR0539-000
Zenhale (inhalation aerosol) Mometasone furoate and formoterol Asthma maintenance (adults, children 12 or older) Do not list Complete February 16, 2011 September 28, 2011 S0225
Afinitor Everolimus Subependymal giant cell astrocytoma associated with tuberous sclerosis complex Do not list Complete March 19, 2014 April 15, 2015 SR0376-000
Afinitor Everolimus renal angiomyolipoma associated with tuberous sclerosis complex (TSC) Do not list Complete March 8, 2013 September 25, 2013 SR0315-000
Aimovig erenumab Migraine Reimburse with clinical criteria and/or conditions Complete May 2, 2019 July 22, 2020 SR0578-000
Ajovy fremanezumab migraine Active June 3, 2020 SR0641-000
Akynzeo netupitant / palonosetron Nausea and vomiting (chemotherapy induced) prevention Reimburse with clinical criteria and/or conditions Complete December 8, 2017 June 20, 2018 SR0548-000
Aldurazyme Laronidase Mucopolysaccharidosis 1 (MPS 1), Hurler, Hurler-Scheie, Scheie Do not list Complete February 3, 2005 July 14, 2005 S0032
Aloxi (injection) Palonosetron hydrochloride Nausea and vomiting (chemotherapy induced) prevention Do not list at the submitted price Complete October 5, 2012 May 15, 2013 SR0293
Aloxi (capsule) Palonosetron Nausea and vomiting (chemotherapy induced) prevention Withdrawn February 6, 2015 SR0415-000
Aloxi (capsule) Palonosetron hydrochloride Nausea and vomiting (chemotherapy induced) prevention Do not list Complete October 5, 2012 April 24, 2013 SR0294
Altace Plus Felodipine Ramipril/felodipine extended release Hypertension Do not list Complete June 22, 2006 November 15, 2006 S0067
Altace HCT Ramipril/hydrochlorothiazide Hypertension Cancelled October 26, 2006 S0083
Altace HCT Ramipril/hydrochlorothiazide Hypertension List Complete March 26, 2007 June 14, 2007 S0095
Alvesco Ciclesonide asthma List Complete July 24, 2006 December 20, 2006 S0074
Amevive Alefacept Psoriasis, moderate to severe chronic plaque Do not list Complete February 28, 2006 September 27, 2006 S0053
Amevive Alefacept Psoriasis, moderate to severe chronic plaque Do not list Complete November 16, 2004 May 26, 2005 S0024
Vocabria and Cabenuva cabotegravir sodium cabotegravir-rilpivirine HIV-1 infection Reimburse with clinical criteria and/or conditions Complete August 19, 2019 July 22, 2020 SR0628-000
Anoro Ellipta Umeclidinium/vilanterol Chronic Obstructive Pulmonary Disease List with criteria/condition Complete February 26, 2014 January 15, 2015 SR0371-000
Apidra Insulin glulisine Diabetes, Mellitus (Type 1 & 2) List in a similar manner to other drugs in class Complete August 29, 2008 February 19, 2009 S0144
Apprilon Doxycycline monohydrate Rosacea treatment Do not list Complete April 27, 2012 March 27, 2013 SR0279
Aptiom Eslicarbazepine acetate Epilepsy, partial-onset seizures List with criteria/condition Complete August 15, 2014 April 16, 2015 SR0391
Aptivus Tipranavir HIV infection List with clinical criteria and/or conditions Complete December 15, 2005 May 17, 2006 S0047
Arbesda RespiClick fluticasone propionate / salmeterol xinafoate Asthma Reimburse with clinical criteria and/or conditions Complete October 4, 2017 December 19, 2018 SR0540-000
Arnuity Ellipta Fluticasone furoate Asthma List with criteria/condition Complete June 26, 2015 December 17, 2015 SR0439-000
ASMANEX Mometasone furoate Asthma, (Bronchial) Prophylactic management of steroid responsive List Complete November 10, 2011 May 16, 2012 SR0258
Atectura Breezhaler indacaterol /mometasone furoate Asthma maintenance (adults, children 12 or older) Active May 19, 2020 SR0646-000
Atripla Efavirenz, emtricitabine, tenofovir disoproxil fumarate HIV List with clinical criteria and/or conditions Complete October 30, 2007 April 17, 2008 S0111
Aubagio Teriflunomide Multiple Sclerosis, relapsing Do not list at the submitted price Complete August 28, 2013 June 18, 2014 SR0350
Somatuline Autogel Lanreotide acetate Acromegaly List in a similar manner to other drugs in class Complete February 20, 2007 July 19, 2007 S0091
Avodart Dutasteride Prostatic hyperplasia, benign List in a similar manner to other drugs in class Complete August 24, 2004 January 20, 2005 S0019
Axert Almotriptan Migraine List in a similar manner to other drugs in class Complete December 24, 2003 May 27, 2004 S0005
Azarga Brinzolamide and timolol maleate suspension Glaucoma and ocular hypertension List in a similar manner to other drugs in class Complete August 28, 2009 February 18, 2010 S0173
Azilect Rasagiline mesylate Parkinson's disease Do not list Complete September 1, 2006 March 28, 2007 S0073
Azilect Rasagiline mesylate Parkinson’s disease Complete March 10, 2009 S0161
Banzel Rufinamide Lennox-Gastaut syndrome; adjunctive treatment of seizures List with clinical criteria and/or conditions Complete September 20, 2011 March 15, 2012 S0252
Baqsimi glucagon Severe hypoglycemic reactions Reimburse with clinical criteria and/or conditions Complete July 24, 2019 January 22, 2020 SR0626-000
Baraclude Entecavir Hepatitis B (chronic) List with clinical criteria and/or conditions Complete December 12, 2006 November 28, 2007 S0089
Basaglar Insulin glargine Diabetes mellitus, Type 1 & 2 List with clinical criteria and/or conditions Complete October 5, 2015 April 14, 2016 SE0451-000
Benlysta Belimumab systemic lupus erythematosus Do not reimburse Complete May 29, 2019 April 22, 2020 SR0616-000
Benlysta Belimumab Systemic lupus erythematosus Do not list Complete September 19, 2011 April 25, 2012 S0251
Beovu brolucizumab Macular degeneration, age-related Reimburse with clinical criteria and/or conditions Complete September 26, 2019 May 21, 2020 SR0632-000
Biktarvy bictegravir/emtricitabine/tenofovir alafenamide HIV-1 infection Reimburse with clinical criteria and/or conditions Complete April 30, 2018 October 25, 2018 SR0567-000
Inflectra (Subsequent Entry Biologic) Infliximab Crohn’s disease and Ulcerative Colitis Reimburse with clinical criteria and/or conditions Complete April 12, 2016 October 25, 2016 SE0483-000
Botox OnabotulinumtoxinA Urinary incontinence List with criteria/condition Complete November 25, 2013 November 12, 2014 SR0362
Botox onabotulinumtoxinA Migraine, chronic Reimburse with clinical criteria and/or conditions Complete November 2, 2018 October 17, 2019 SR0584-000
Botox OnabotulinumtoxinA Migraine, chronic Do not list Complete August 15, 2013 May 28, 2014 SR0345
Botox OnabotulinumtoxinA Neurogenic Detrusor Overactivity List with clinical criteria and/or conditions Complete January 31, 2012 July 19, 2012 SR0268
Ultibro Breezhaler Indacaterol/glycopyrronium COPD List with criteria/condition Complete February 3, 2014 December 19, 2014 SR0369-000
Enerzair Breezhaler indacaterol glycopyrronium mometasone furoate Asthma maintenance, adults Active May 19, 2020 SR0645-000
Brenzys Etanercept Rheumatoid arthritis, ankylosing spondylitis Reimburse with clinical criteria and/or conditions Complete April 20, 2016 October 25, 2016 SE0485-000
Breo Ellipta fluticasone furoate/vilanterol Asthma Withdrawn May 2, 2018 SR0568-000
Breo Ellipta Fluticasone Furoate and Vilanterol (as trifenatate) Asthma List with clinical criteria and/or conditions Complete August 10, 2015 February 18, 2016 SR0442-000
Breo Ellipta fluticasone furoate/vilanterol COPD Withdrawn June 28, 2017 SR0524-000
Breo Ellipta Fluticasone furoate /vilanterol Chronic Obstructive Pulmonary Disease (COPD) List with criteria/condition Complete October 29, 2013 August 18, 2014 SR0358
Brilinta Ticagrelor Acute Coronary Syndromes (ACS) Cancelled June 8, 2010 S0203
Brilinta Ticagrelor Thrombotic events in Acute Coronary Syndromes, Prevention Do not list Complete June 1, 2011 December 16, 2011 S0234
Brilinta ticagrelor Prevention of atherothrombotic events with history of myocardial infarction Reimburse with clinical criteria and/or conditions Complete February 18, 2016 August 25, 2016 SR0474-000
Brineura cerliponase alfa Neuronal Ceroid Lipofuscinosis Type 2 Reimburse with clinical criteria and/or conditions Complete July 31, 2018 May 23, 2019 SR0574-000
Brivlera Brivaracetam Epilepsy, partial-onset seizures Reimburse with clinical criteria and/or conditions Complete April 19, 2016 January 25, 2017 SR0484-000
BuTrans Buprenorphine transdermal patch Pain, persistent (moderate intensity) Do not list Complete May 9, 2011 September 28, 2011 S0233
BuTrans Buprenorphine transdermal patch Pain, persistent (moderate intensity) Cancelled October 15, 2010 S0211
Byetta Exenatide Diabetes mellitus, Type 2 Do not list Complete August 23, 2011 July 19, 2012 S0246
Bystolic Nebivolol Hypertension, essential Do not list at the submitted price Complete February 4, 2013 July 18, 2013 SR0307
Cablivi caplacizumab Acquired thrombotic thrombocytopenic purpura (aTTP) Do not reimburse Complete September 13, 2019 August 26, 2020 SR0633-000
Caduet Amlodipine besylate/ atorvastatin calcium Hypertension/ Dyslipidemia List with clinical criteria and/or conditions Complete December 15, 2005 May 17, 2006 S0048
Campral Acamprosate calcium Alcohol Abstinence Complete July 22, 2008 S0143
Campral Acamprosate calcium Alcohol Abstinence List with clinical criteria and/or conditions Complete August 29, 2007 March 27, 2008 S0108
Cayston Aztreonam for inhalation solution Cystic fibrosis (CF) with chronic pulmonary pseudomonas aeruginosa infections List with clinical criteria and/or conditions Complete December 2, 2010 July 18, 2011 S0220
Celsentri Maraviroc HIV Withdrawn November 2, 2007 S0113
Celsentri Maraviroc HIV List with clinical criteria and/or conditions Complete May 7, 2008 November 12, 2008 S0136
Celsentri Maraviroc HIV-1, treatment naïve (adult) Do not list Complete December 8, 2010 July 18, 2011 S0221
Cerdelga Eliglustat Gaucher disease Reimburse with clinical criteria and/or conditions Complete January 20, 2017 July 26, 2017 SR0511-000
Champix Varenicline tartrate Smoking-cessation List with clinical criteria and/or conditions Complete March 21, 2007 August 16, 2007 S0094
Cimzia Certolizumab pegol Arthritis, rheumatoid Do not list Complete September 3, 2009 May 27, 2010 S0175
Cimzia Certolizumab pegol Arthritis, psoriatic List with criteria/condition Complete September 2, 2014 April 17, 2015 SR0394
Cimzia certolizumab pegol Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Complete May 13, 2019 November 20, 2019 SR0587-000
Cimzia Certolizumab pegol Ankylosing spondylitis List with criteria/condition Complete June 23, 2014 April 17, 2015 SR0385-000
Cinqair reslizumab Asthma, eosinophilic Reimburse with clinical criteria and/or conditions Complete October 24, 2018 March 27, 2019 SF0591-000
Cinqair Reslizumab Asthma, eosinophilic Reimburse with clinical criteria and/or conditions Complete August 4, 2016 March 22, 2017 SR0495-000
Cipralex Escitalopram oxalate Depression, Major Depressive Disorder (MDD) Do not list Complete June 8, 2006 January 24, 2007 S0064
Cipralex Escitalopram oxalate Depression, Major Depressive Disorder (MDD) Withdrawn August 3, 2005 S0039
Ciprodex Ciprofloxacin hydrochloride & dexamethasone otic suspension Otitis media with otorrhea & otitis externa, acute List with clinical criteria and/or conditions Complete June 15, 2007 October 18, 2007 S0101
Ciprodex Ciprofloxacin hydrochloride and dexamethasone otic suspension Otitis media with otorrhea & otitis externa, acute Do not list Complete June 11, 2004 January 26, 2005 S0014
Combigan Ophthalmic Solution Brimonidine tartrate/timolol maleate Glaucoma List with clinical criteria and/or conditions Complete December 15, 2003 May 27, 2004 S0001
COMPLERA Emtricitabine/ rilpivirine/ tenofovir disoproxil fumarate HIV-1 infection in antiretroviral treatment- naïve adults List Complete October 19, 2011 April 19, 2012 S0256
Constella Linaclotide Irritable bowel syndrome with constipation Do not list Complete December 17, 2014 September 23, 2015 SR0409-000
Contrave naltrexone hydrochloride and bupropion hydrochloride Chronic weight management in adults Do not reimburse Complete May 1, 2019 May 27, 2020 SR0610-000
Copaxone Glatiramer acetate Clinically Isolated Syndrome (CIS), suggestive of Multiple Sclerosis Do not list Complete April 29, 2009 November 25, 2009 S0164
Cortiment Budesonide Ulcerative Colitis Do not reimburse Complete May 24, 2016 March 22, 2017 SR0491-000
Cosentyx Secukinumab Arthritis, psoriatic Reimburse with clinical criteria and/or conditions Complete February 19, 2016 August 23, 2016 SR0476-000
Cosentyx Secukinumab Psoriasis, moderate to severe plaque List with criteria/condition Complete December 8, 2014 October 28, 2015 SR0407-000
Cosentyx Secukinumab Ankylosing spondylitis Reimburse with clinical criteria and/or conditions Complete February 19, 2016 August 23, 2016 SR0475-000
Nucynta CR Tapentadol Pain, moderate to moderately severe Do not list Complete February 1, 2011 September 28, 2011 S0224
Cresemba isavuconazole Treatment of invasive aspergillosis and mucormycosis Reimburse with clinical criteria and/or conditions Complete November 2, 2018 May 15, 2019 SR0586-000
Crysvita burosumab Treatment of X-Linked Hypophosphatemia Reimburse with clinical criteria and/or conditions Complete July 23, 2019 May 27, 2020 SR0602-000
Cubicin Daptomycin Skin and skin structure infections & bacteremia Do not list Complete March 6, 2008 September 24, 2008 S0127
Cuvposa glycopyrrolate chronic severe drooling, neurologic (pediatric) Do not reimburse Complete May 31, 2019 June 24, 2020 SR0613-000
Cymbalta Duloxetine hydrochloride Depressive, Major Disorder (MDD) Do not list Complete February 8, 2008 August 14, 2008 S0125
Cymbalta Duloxetine hydrochloride Pain, Neuropathic, Diabetic List with clinical criteria and/or conditions Complete February 8, 2008 August 14, 2008 S0126
Cystadrops cysteamine Corneal cystine crystal deposits Reimburse with clinical criteria and/or conditions Complete December 10, 2018 June 18, 2019 SR0595-000
Daklinza daclatasvir Hepatitis C, chronic Reimburse with clinical criteria and/or conditions Complete January 6, 2016 May 19, 2016 SF0467-000
Daklinza Daclatasvir Hepatitis C, chronic List with clinical criteria and/or conditions Complete February 13, 2015 September 21, 2015 SR0417-000
Daxas Roflumilast Chronic obstructive pulmonary disease (COPD) Do not list Complete November 30, 2010 July 27, 2011 S0218
Delstrigo doravirine lamuvidine tenofovir disoproxil fumarate HIV-1 infection Reimburse with clinical criteria and/or conditions Complete November 16, 2018 May 14, 2019 SR0581-000
Denavir Penciclovir Herpes labialis (cold sores) Do not list Complete September 20, 2006 April 26, 2007 S0075
Descovy Emtricitabine /tenofovir alafenamide HIV-1 infection Reimburse with clinical criteria and/or conditions Complete January 29, 2016 August 24, 2016 SR0470-000
Diacomit Stiripentol Dravet Syndrome List with criteria/condition Complete October 30, 2013 October 16, 2014 SR0360-000
Dificid Fidaxomicin Clostridium difficile infection Do not list at the submitted price Complete July 10, 2012 December 19, 2012 SR0285
Dovato dolutegravir / lamivudine HIV-1 infection Reimburse with clinical criteria and/or conditions Complete February 21, 2019 September 30, 2019 SR0601-000
Duaklir Genuair Aclidinium bromide/formoterol fumarate dihydrate Chronic Obstructive Pulmonary Disease (COPD) List with clinical criteria and/or conditions Complete April 1, 2015 September 18, 2015 SR0423-000
Duobrii Halobetasol propionate and tazarotene Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Active January 24, 2020 October 28, 2020 SR0638-000
Duodopa Levodopa / carbidopa (Drug Plan Submission) Parkinson's disease Reimburse with clinical criteria and/or conditions Complete February 8, 2018 August 22, 2018 SR0557-000
Duodopa Levodopa / carbidopa Parkinson's disease Do not list Complete December 19, 2008 July 22, 2009 S0154
DuoTrav Travoprost and timolol maleate Glaucoma List with clinical criteria and/or conditions Complete March 24, 2006 August 24, 2006 S0057
Dupixent dupilumab atopic dermatitis Do not reimburse Complete October 27, 2017 June 27, 2018 SR0533-000
Dupixent dupilumab atopic dermatitis Reimburse with clinical criteria and/or conditions Complete October 22, 2019 April 22, 2020 SR0636-000
Dupixent dupilumab Indicated in adults and adolescents 12 years and older as an add-on maintenance treatment for moderate-to-severe asthma characterized by type 2 inflammation. Indicated as maintenance therapy to improve lung function. Indicated as maintenance therapy for oral corticosteroid-dependent asthma irrespective of type 2 inflammatory markers. Pending SR0667-000
Dymista Azelastine HCl and fluticasone propionate Seasonal allergic rhinitis Do not list Complete December 9, 2014 June 17, 2015 SR0408-000
Dysport Therapeutic abobotulinumtoxinA lower limb spasticity Reimburse with clinical criteria and/or conditions Complete February 7, 2018 August 23, 2018 SR0556-000
Dysport Therapeutic abobotulinumtoxinA Upper limb spasticity Reimburse with clinical criteria and/or conditions Complete April 24, 2017 October 24, 2017 SR0517-000
Dysport Therapeutic abobotulinumtoxinA Cervical dystonia Reimburse with clinical criteria and/or conditions Complete January 31, 2017 July 26, 2017 SR0512-000
Ebixa Memantine hydrochloride Dementia (Alzheimer type), moderate to severe Do not list Complete December 21, 2004 November 23, 2005 S0025
Edarbi Azilsartan medoxomil Hypertension, essential Do not list at the submitted price Complete March 8, 2013 October 17, 2013 SR0317
Edarbyclor Azilsartan medoxomil + chlorthalidone Hypertension, essential Do not list Complete March 8, 2013 October 17, 2013 SR0318
Edurant Rilpivirine HIV (treatment - naive adult) List Complete July 29, 2011 February 15, 2012 S0243
Effient Prasugrel Acute Coronary Syndrome (ACS) Do not list Complete December 12, 2011 June 14, 2012 S0263
Effient Prasugrel hydrochloride Acute Coronary Syndrome (ACS) Do not list Complete May 5, 2010 February 16, 2011 S0200
Egrifta Tesamorelin Lipodystrophy, HIV-infected patients Do not reimburse Complete March 2, 2016 August 24, 2016 SR0477-000
Elaprase Idursulfase Mucopolysaccharidosis II (MPS II), Hunter Syndrome Do not list Complete July 13, 2007 December 19, 2007 S0104
Elelyso Taliglucerase alfa Gaucher disease Do not list Complete August 15, 2014 October 28, 2015 SR0390
Eliquis Apixaban Thromboembolic events prevention, (atrial fibrillation) List with clinical criteria and/or conditions Complete September 25, 2012 March 20, 2013 SR0288
Eliquis Apixaban Thromboembolic events, (venous) prevention List with clinical criteria and/or conditions Complete December 20, 2011 June 14, 2012 S0264
Eliquis Apixaban Thromboembolic events (venous), treatment and prevention of recurrence List with clinical criteria and/or conditions Complete September 18, 2014 May 7, 2015 SR0397-000
Trelegy Ellipta fluticasone furoate umeclidinium vilanterol Chronic obstructive pulmonary disease (COPD) Reimburse with clinical criteria and/or conditions Complete March 1, 2018 August 23, 2018 SR0562-000
Incruse Ellipta Umeclidinium Chronic Obstructive Pulmonary Disease (COPD) List with criteria/condition Complete March 4, 2015 September 18, 2015 SR0422-000
Emend Aprepitant Nausea and Vomiting, Chemotherapy induced List with clinical criteria and/or conditions Complete August 29, 2007 February 20, 2008 S0109
Restasis ophthalmic emulsion Cyclosporine Dry eye disease, Moderate to moderately severe Do not list Complete December 17, 2010 July 18, 2011 S0222
Enablex Darifenacin hydrobromide Bladder, overactive List with clinical criteria and/or conditions Complete October 1, 2008 April 16, 2009 S0147
Enablex Darifenacin hydrobromide Bladder, overactive Do not list Complete April 26, 2006 October 19, 2006 S0061
Enspryng satralizumab Neuromyelitis optica spectrum disorder Pending SR0663-000
Entresto Sacubitril/valsartan Heart failure, NYHA class II or III List with clinical criteria and/or conditions Complete September 18, 2015 March 18, 2016 SR0447-000
Entresto sacubitril/valsartan Heart failure, NYHA Class II or III Active May 22, 2020 SR0644-000
Entyvio vedolizumab Crohn’s disease Active July 23, 2020 SR0647-000
Entyvio Vedolizumab Ulcerative Colitis List with clinical criteria and/or conditions Complete February 20, 2015 October 28, 2015 SR0421-000
Entyvio Vedolizumab Crohn’s disease Reimburse with clinical criteria and/or conditions Complete April 27, 2016 October 31, 2016 SR0487-000
Entyvio vedolizumab Ulcerative Colitis Reimburse with clinical criteria and/or conditions Complete November 21, 2019 May 19, 2020 SR0635-000
Epclusa Sofosbuvir/ velpatasvir Hepatitis C, chronic Reimburse with clinical criteria and/or conditions Complete April 22, 2016 October 26, 2016 SR0486-000
Erelzi Etanercept Ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, rheumatoid arthritis Reimburse with clinical criteria and/or conditions Complete February 2, 2017 July 25, 2017 SE0513-000
Esbriet Pirfenidone Pulmonary fibrosis (idiopathic, mild to moderate) Do not list Complete October 5, 2012 April 18, 2013 SR0292
Esbriet Pirfenidone Pulmonary fibrosis (idiopathic, mild to moderate) List with criteria/condition Complete August 29, 2014 April 15, 2015 SR0393
Eucrisa crisaborole atopic dermatitis Do not reimburse Complete May 25, 2018 March 27, 2019 SR0570-000
Evra Norgelestromin/ethinyl estradiol Contraceptive, patch Do not list Complete December 19, 2003 June 23, 2004 S0004
Exelon Patch Rivastigmine Dementia (Alzheimer's type) Do not list Complete December 21, 2007 July 23, 2008 S0123
Exjade Deferasirox Iron overload List with clinical criteria and/or conditions Complete October 26, 2006 April 19, 2007 S0081
Eylea Aflibercept Macular edema, diabetic List with clinical criteria and/or conditions Complete September 16, 2014 May 7, 2015 SR0396-000
Eylea Aflibercept Macular edema secondary to central retinal vein occlusion List with clinical criteria and/or conditions Complete October 17, 2014 May 7, 2015 SR0401-000
Eylea Aflibercept Macular degeneration, age-related List with criteria/condition Complete November 18, 2013 October 20, 2014 SR0361-000
Eylea Aflibercept Macular edema secondary to branch retinal vein occlusion Reimburse with clinical criteria and/or conditions Complete December 14, 2015 July 27, 2016 SR0460-000
Fabrazyme Agalsidase beta Fabry Disease Do not list Complete February 24, 2004 November 24, 2004 S0007
Fabrazyme Agalsidase beta Fabry Disease Do not list Complete December 10, 2004 May 18, 2005 S0028
Fampyra Fampridine Multiple Sclerosis, improve walking disability Do not list Complete April 16, 2012 November 28, 2012 SR0275
Fampyra Fampridine Multiple Sclerosis, improve walking disability Withdrawn November 6, 2014 SR0404-000
Fasenra benralizumab Asthma, severe eosinophilic Reimburse with clinical criteria and/or conditions Complete October 24, 2018 March 27, 2019 SF0592-000
Fasenra benralizumab Asthma, severe eosinophilic Reimburse with clinical criteria and/or conditions Complete February 23, 2018 August 21, 2018 SR0561-000
Fentora Fentanyl buccal Pain (breakthrough), cancer (adults) Do not reimburse Complete July 12, 2016 February 21, 2017 SR0494-000
Ferriprox Deferiprone Transfusional iron overload List with clinical criteria and/or conditions Complete September 24, 2015 March 18, 2016 SR0448-000
Fibristal ulipristal acetate Uterine fibroids (signs and symptoms) Reimburse with clinical criteria and/or conditions Complete June 21, 2017 November 22, 2017 SF0528-000
Fibristal ulipristal acetate Uterine fibroids (signs and symptoms) Reimburse with clinical criteria and/or conditions Complete March 28, 2019 July 24, 2019 SF0609-000
Fibristal Ulipristal acetate Uterine fibroids (signs and symptoms) List with criteria/condition Complete April 17, 2013 November 15, 2013 SR0326
Finacea Azelaic acid Rosacea List Complete August 31, 2010 February 16, 2011 S0209
Firazyr Icatibant Angioedema, hereditary List with clinical criteria and/or conditions Complete March 4, 2014 December 19, 2014 SR0375-000
Firazyr icatibant Acute attacks of hereditary angioedema in adolescents and children aged two years and older with C1-esterase inhibitor deficiency CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer NotFiled
Forteo Teriparatide (rDNA origin) injection Osteoporosis Do not list Complete June 8, 2004 December 22, 2004 S0015
Forteo Teriparatide (rDNA origin) injection Osteoporosis, glucocorticoid induced Do not list Complete December 18, 2008 July 22, 2009 S0152
Forteo Teriparatide (rDNA origin) injection Osteoporosis (in women), Severe Do not list Complete October 23, 2009 March 17, 2010 S0180
Forteo Teriparatide (rDNA origin) injection Osteoporosis Withdrawn May 29, 2006 S0065
Forteo Teriparatide (rDNA origin) injection Osteoporosis Withdrawn June 12, 2009 S0169
Forteo Teriparatide (rDNA origin) injection Osteoporosis Withdrawn December 18, 2008 S0157
Forxiga Dapagliflozin Diabetes mellitus, type 2 Do not list Complete September 4, 2015 April 27, 2016 SR0445-000
Forxiga dapagliflozin Heart failure with reduced ejection fraction Active March 31, 2020 SR0642-000
Forxiga Dapagliflozin Diabetes mellitus (Type 2) List with clinical criteria and/or conditions Complete April 30, 2015 November 20, 2015 SR0428-000
Fosavance Alendronate sodium/cholecalciferol Osteoporosis Do not list Complete March 27, 2006 September 27, 2006 S0059
Fosrenol Lanthanum carbonate hydrate Hyperphosphatemia, end-stage renal disease Do not list Complete June 28, 2007 January 30, 2008 S0100
Fulphila pegfilgrastim Febrile neutropenia in non-myeloid malignancies Complete November 14, 2018 SE0588-000
Fycompa Perampanel Epilepsy, partial onset seizures List with criteria/condition Complete March 8, 2013 October 17, 2013 SR0316-000
Fycompa Perampanel Epilepsy, primary generalized tonic-clonic seizures Reimburse with clinical criteria and/or conditions Complete November 24, 2015 May 18, 2016 SR0458-000
Galafold migalastat Fabry Disease Reimburse with clinical criteria and/or conditions Complete June 9, 2017 January 24, 2018 SR0522-000
Galexos Simeprevir Hepatitis C, chronic List with criteria/condition Complete August 22, 2013 June 18, 2014 SR0347
Gelnique Oxybutynin Chloride Gel Bladder, overactive Do not list Complete October 25, 2011 May 24, 2012 S0260
Genotropin Somatropin Growth hormone deficiency, adult List with criteria/condition Complete May 27, 2013 December 20, 2013 SR0332
Genotropin Somatropin Growth hormone deficiency, pediatric List with criteria/condition Complete May 27, 2013 December 20, 2013 SR0333
Genotropin Somatropin Turner Syndrome List with criteria/condition Complete May 27, 2013 December 20, 2013 SR0334
Tudorza Genuair Aclidinium bromide Chronic Obstructive Pulmonary Disease (COPD) List with criteria/condition Complete August 21, 2013 April 21, 2014 SR0346
Genvoya Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide HIV-1 infection List Complete September 24, 2015 March 18, 2016 SR0449-000
Gilenya Fingolimod Multiple Sclerosis List with clinical criteria and/or conditions Complete May 10, 2011 November 16, 2011 S0228
Glatect Glatiramer acetate Multiple Sclerosis, relapsing - remitting Reimburse with clinical criteria and/or conditions Complete January 20, 2017 July 25, 2017 SE0510
Grastek Phleum pratense Allergy (grass) Do not list Complete September 30, 2013 September 24, 2014 SR0352
Grastofil Filgrastim Prevention or treatment of neutropenia in various indications List with clinical criteria and/or conditions Complete September 11, 2015 March 18, 2016 SE0446-000
Harvoni Ledipasvir / Sofosbuvir Hepatitis C, chronic List with criteria/condition Complete September 15, 2014 March 18, 2015 SR0395
Harvoni ledipasvir, sofosbuvir Hepatitis C, chronic Reimburse with clinical criteria and/or conditions Complete January 6, 2016 May 18, 2016 SF0465-000
Hemangiol Propranolol oral solution Infantile hemangioma Reimburse with clinical criteria and/or conditions Complete August 25, 2016 February 21, 2017 SR0496-000
Hemangiol Propranolol Infantile hemangioma Withdrawn December 23, 2014 SR0411-000
Hemlibra emicizumab Bleeding prevention, hemophilia A Active June 30, 2020 ST0651-000
Hepsera Adefovir dipivoxil Hepatitis B List with clinical criteria and/or conditions Complete June 29, 2007 October 18, 2007 S0103
Hepsera Adefovir dipivoxil Hepatitis B Do not list Complete April 24, 2006 November 29, 2006 S0060
Holkira Pak Ombitasvir/paritaprevir/ritonavir and dasabuvir Hepatitis C, chronic List with clinical criteria and/or conditions Complete December 3, 2014 June 18, 2015 SR0406-000
Holkira Pak ombitasvir/paritaprevir/ritonavir and dasabuvir Hepatitis C, chronic Reimburse with clinical criteria and/or conditions Complete January 6, 2016 May 19, 2016 SF0466-000
Humira Adalimumab Crohn's disease List with clinical criteria and/or conditions Complete July 12, 2007 December 19, 2007 S0105
Humira Adalimumab Arthritis, Rheumatoid List with clinical criteria and/or conditions Complete September 24, 2004 February 11, 2005 S0022
Humira Adalimumab Arthritis, Juvenile Idiopathic List with clinical criteria and/or conditions Complete February 4, 2013 July 18, 2013 SR0308
Humira Adalimumab Ankylosing spondylitis (AS) List with clinical criteria and/or conditions Complete November 17, 2006 June 27, 2007 S0087
Humira Adalimumab Ulcerative Colitis Do not list at the submitted price Complete September 25, 2015 April 15, 2016 SR0450-000
Humira Adalimumab Ulcerative colitis Withdrawn December 23, 2013 SR0365
Humira Adalimumab Psoriasis List with clinical criteria and/or conditions Complete April 15, 2008 October 16, 2008 S0130
Humira Adalimumab Arthritis, Psoriatic List with clinical criteria and/or conditions Complete June 21, 2006 November 29, 2006 S0066
Humira Adalimumab Hidradenitis suppurativa Reimburse with clinical criteria and/or conditions Complete November 3, 2015 May 19, 2016 SR0455-000
Simponi I.V. Golimumab Arthritis, Rheumatoid List with criteria/condition Complete September 12, 2013 July 17, 2014 SR0351
Stelara/Stelara I.V. ustekinumab Crohn’s disease Reimburse with clinical criteria and/or conditions Complete September 12, 2016 March 21, 2017 SR0501-000
Stelara/Stelara I.V ustekinumab Ulcerative colitis Reimburse with clinical criteria and/or conditions Complete August 12, 2019 July 16, 2020 SR0627-000
Ikervis cyclosporine keratitis, severe Withdrawn May 15, 2017 SR0518-000
Ilaris Canakinumab Cryopyrin-Associated Periodic Syndrome (CAPS) Do not list Complete July 7, 2010 January 26, 2011 S0204
Ilaris Canakinumab Systemic juvenile idiopathic arthritis Reimburse with clinical criteria and/or conditions Complete December 23, 2015 June 17, 2016 SR0463-000
Ilumya tildrakizumab Psoriasis, moderate to severe plaque Suspended July 15, 2019 SR0624-000
Iluvien fluocinolone acetonide Diabetic macular edema (DME) Withdrawn December 21, 2017 SR0549-000
Iluvien fluocinolone acetonide intravitreal implant diabetic macular edema Do not reimburse Complete April 3, 2019 September 26, 2019 SR0608-000
Imbruvica ibrutinib Chronic graft versus host disease CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer NotFiled
Incivek Telaprevir Hepatitis C infection (genotype 1), Chronic List with clinical criteria and/or conditions Complete August 23, 2011 February 15, 2012 S0249
Incivek Telaprevir Hepatitis C infection, chronic List with criteria/condition Complete February 19, 2013 June 13, 2013 SF0311
Incivek Telaprevir Hepatitis C, chronic List with criteria/condition Complete December 21, 2012 June 13, 2013 SF0305-000
Inflectra Infliximab Ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis List with criteria/condition Complete June 17, 2014 December 19, 2014 SE0384-000
Inspiolto Respimat Tiotropium / olodaterol Chronic Obstructive Pulmonary Disease (COPD) List with criteria/condition Complete June 4, 2015 December 17, 2015 SR0436-000
Inspra Eplerenone Heart failure, NYHA class II Do not list at the submitted price Complete July 12, 2013 April 24, 2014 SR0342
Inspra Eplerenone Post myocardial infarction Do not list Complete May 6, 2009 November 25, 2009 S0165
Intelence Etravirine HIV List with clinical criteria and/or conditions Complete April 2, 2008 August 14, 2008 S0129
Intuniv XR Guanfacine hydrochloride Attention-deficit/hyperactivity disorder (ADHD) Do not list Complete August 27, 2013 September 24, 2014 SR0349-000
Invega Paliperidone Schizophrenia Do not list Complete November 1, 2007 May 28, 2008 S0112
Invega Sustenna Paliperidone palmitate Schizophrenia Do not list Complete July 9, 2010 April 25, 2011 S0206
Invokamet Canagliflozin and metformin hydrochloride Diabetes mellitus, type 2 Reimburse with clinical criteria and/or conditions Complete March 3, 2016 August 25, 2016 SR0480-000
Invokana Canagliflozin Diabetes mellitus, type 2 Withdrawn June 5, 2013 SR0335
Invokana Canagliflozin Diabetes Mellitus, Type 2 List with criteria/condition Complete February 24, 2014 January 15, 2015 SR0370-000
Iressa Gefitinib Cancer, Lung , non-small cell Do not list Complete December 22, 2003 June 23, 2004 S0003
Isentress Raltegravir HIV List with clinical criteria and/or conditions Complete November 29, 2007 May 14, 2008 S0115
Isentress Raltegravir HIV (treatment naïve) Do not list Complete December 4, 2009 June 23, 2010 S0191
Izba travoprost ophthalmic solution open-angle glaucoma Reimburse with clinical criteria and/or conditions Complete March 1, 2017 October 25, 2017 SR0516-000
Janumet Sitagliptin phosphate monohydrate / metformin hydrochloride Diabetes mellitus (Type 2) List with clinical criteria and/or conditions Complete November 4, 2009 June 23, 2010 S0182
Januvia Sitagliptin phosphate Diabetes mellitus (Type 2) Do not list Complete December 20, 2007 June 18, 2008 S0122
Januvia Sitagliptin phosphate Diabetes mellitus (Type 2) List with clinical criteria and/or conditions Complete October 29, 2009 June 23, 2010 S0181
Jardiance Empagliflozin Diabetes mellitus, type 2 with high cardiovascular risk Reimburse with clinical criteria and/or conditions Complete April 27, 2016 October 26, 2016 SR0488-000
Jardiance Empagliflozin Diabetes mellitus (Type 2) List with clinical criteria and/or conditions Complete April 23, 2015 October 15, 2015 SR0427-000
Jentadueto Linagliptin-metformin Diabetes mellitus (Type 2) List with criteria/condition Complete March 8, 2013 October 17, 2013 SR0306
Jetrea Ocriplasmin Vitreomacular adhesion List with criteria/condition Complete June 6, 2013 December 20, 2013 SR0337
Jinarc Tolvaptan Autosomal dominant polycystic kidney disease (ADPKD) Do not list Complete May 29, 2015 February 24, 2016 SR0435-000
Jorveza budesonide Eosinophilic esophagitis, adults Reimburse with clinical criteria and/or conditions Active November 8, 2019 October 28, 2020 SR0634-000
Jorveza budesonide Maintenance of Eosinophilic esophagitis in adults Pending SR0666-000
Jublia efinaconazole Onychomycosis Do not reimburse Complete August 2, 2018 May 23, 2019 SR0577-000
Juluca Dolutegravir rilpivirine HIV infection Reimburse with clinical criteria and/or conditions Complete December 21, 2017 June 20, 2018 SR0551-000
Jurnista Hydromorphone hydrochloride Pain, Chronic (moderate to severe) Do not list Complete December 4, 2009 May 19, 2010 S0190
Juxtapid Lomitapide Hypercholesterolemia, Homozygous Familial Do not list Complete July 8, 2014 April 17, 2015 SR0386-000
Kalydeco Ivacaftor Cystic Fibrosis (CFTR gating mutations) List with criteria/condition Complete May 1, 2014 December 19, 2014 SR0379-000
Kalydeco Ivacaftor Cystic Fibrosis, R117H CFTR gating mutation List with criteria/condition Complete May 8, 2015 November 19, 2015 SR0430-000
Kalydeco Ivacaftor Cystic Fibrosis patients (G551D mutation) List with criteria/condition Complete September 27, 2012 March 22, 2013 SR0291
Kanuma sebelipase alfa Lysosomal acid lipase deficiency Reimburse with clinical criteria and/or conditions Complete November 2, 2017 September 26, 2018 SR0544-000
Kazano Alogliptin plus metformin Diabetes mellitus (Type 2) Do not list Complete January 30, 2014 January 15, 2015 SR0367-000
Kevzara sarilumab Arthritis, Rheumatoid Reimburse with clinical criteria and/or conditions Complete October 12, 2016 April 18, 2017 SR0503-000
Kivexa Abacavir/lamivudine HIV infection List in a similar manner to other drugs in class Complete July 26, 2005 December 7, 2005 S0038
Komboglyze Saxagliptin + metformin Diabetes Mellitus, Type 2 Withdrawn June 6, 2013 SR0336
Komboglyze Saxagliptin + metformin Diabetes Mellitus, Type 2 List with criteria/condition Complete August 23, 2013 June 20, 2014 SR0348
Kuvan Sapropterin dihydrochloride Phenylketonuria (PKU) Reimburse with clinical criteria and/or conditions Complete February 1, 2016 October 26, 2016 SR0472-000
Kuvan Sapropterin dihydrochloride Phenylketonuria (PKU). Do not list Complete July 8, 2010 January 26, 2011 S0205
Kuvan Sapropterin dihydrochloride Phenylketonuria (PKU). Complete June 1, 2011 S0236
Kynmobi apomorphine hydrochloride Parkinson’s disease Active June 25, 2020 SR0650-000
Kynmobi apomorphine hydrochloride Parkinson’s Disease Withdrawn February 25, 2019 SR0604-000
Lancora Ivabradine Heart failure, NYHA class II or III Reimburse with clinical criteria and/or conditions Complete November 8, 2016 May 24, 2017 SR0506-000
Lantus Insulin glargine (rDNA origin) Diabetes mellitus, Type 1 & 2 Complete June 9, 2009 S0166
Lantus Insulin glargine (rDNA origin) Diabetes mellitus, Type 1 & 2 Do not list Complete February 11, 2005 September 28, 2005 S0033
Lantus Insulin glargine (rDNA origin) Diabetes mellitus, Type 1 & 2 Do not list Complete March 27, 2006 October 25, 2006 S0058
Lapelga Pegfilgrastim Febrile neutropenia Complete February 23, 2018 SE0555-000
Latuda Lurasidone Schizophrenia List with criteria/condition Complete May 9, 2013 December 20, 2013 SR0331
Latuda Lurasidone schizophrenia Do not list Complete July 3, 2012 January 23, 2013 SR0284
Latuda lurasidone Bipolar I disorder CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer NotFiled
Lemtrada Alemtuzumab Multiple Sclerosis, relapsing-remitting List with criteria/condition Complete November 27, 2014 June 18, 2015 SR0405-000
Lemtrada Alemtuzumab Multiple Sclerosis, relapsing Withdrawn October 1, 2013 SR0355
Levemir Insulin detemir Diabetes mellitus Do not list Complete December 19, 2005 August 2, 2006 S0049
Levemir Insulin detemir Diabetes mellitus Do not list Complete March 10, 2009 August 20, 2009 S0160
Levemir Insulin detemir Diabetes mellitus Withdrawn February 2, 2009 S0158
Levemir Insulin detemir Diabetes mellitus Type1, Pediatrics Do not list Complete March 10, 2009 August 20, 2009 S0172
pdp-levETIRAcetam Levetiracetam Epilepsy Active July 17, 2020 SR0653-000
Lixiana VTE Edoxaban Venous thromboembolism, treatment and recurrence prevention Reimburse with clinical criteria and/or conditions Complete September 9, 2016 May 25, 2017 SR0499-000
Lixiana NVAF Edoxaban Nonvalvular atrial fibrillation, prevention of stroke and systemic embolism Reimburse with clinical criteria and/or conditions Complete September 9, 2016 March 21, 2017 SR0500-000
Lodalis Colesevelam hydrochloride Hypercholesterolemia Do not list at the submitted price Complete April 27, 2012 December 19, 2012 SR0274
Lokelma sodium zirconium cyclosilicate Hyperkalemia, adults Do not reimburse Complete May 17, 2019 March 25, 2020 SR0612-000
Lotemax Loteprednol etabonate Post-operative inflammation following cataract surgery Do not list Complete December 2, 2009 May 19, 2010 S0186
Lucentis Ranibizumab Macular degeneration, age-related List with clinical criteria and/or conditions Complete July 12, 2007 March 27, 2008 S0098
Lucentis Ranibizumab Choroidal neovascularisation, myopic List with criteria/condition Complete February 28, 2014 February 19, 2015 SR0373-000
Lucentis Ranibizumab injection Macular edema, secondary to retinal vein occlusion List with clinical criteria and/or conditions Complete April 25, 2012 October 18, 2012 SR0276
Lucentis Ranibizumab Macular edema, diabetic List with clinical criteria and/or conditions Complete September 14, 2011 March 19, 2012 S0253
Luxturna voretigene neparvovec Vision loss, inherited retinal dystrophy Active April 23, 2020 SG0643-000
Lyrica Pregabalin diabetic peripheral neuropathy Do not list Complete March 20, 2009 September 23, 2009 S0162
Lyrica Pregabalin Pain, Neuropathic Do not list Complete June 27, 2005 January 25, 2006 S0036
Pantoloc M Pantoprazole magnesium Gastric acid secretion, reduction of List in a similar manner to other drugs in class Complete March 17, 2006 July 20, 2006 S0054
Macugen Pegaptanib sodium Macular degeneration, age-related Do not list Complete October 20, 2005 May 25, 2006 S0044
Mavenclad cladribine Multiple Sclerosis, relapsing Reimburse with clinical criteria and/or conditions Complete December 1, 2017 October 24, 2018 SR0546-000
Maviret glecaprevir pibrentasvir Hepatitis C, chronic Reimburse with clinical criteria and/or conditions Complete June 9, 2017 January 23, 2018 SR0523-000
Mayzent siponimod Secondary progressive multiple sclerosis Reimburse with clinical criteria and/or conditions Complete September 26, 2019 July 21, 2020 SR0631-000
MDK-Nitisinone nitisinone Hereditary tyrosinemia type 1 Reimburse with clinical criteria and/or conditions Complete September 29, 2017 April 25, 2018 SR0538-000
Mictoryl Propiverine hydrochloride Overactive bladder (OAB) Reimburse with clinical criteria and/or conditions Complete October 14, 2016 April 19, 2017 SR0504-000
Mifegymiso Mifepristone and misoprostol Medical termination of pregnancy (gestational age up to 49 days) Withdrawn February 12, 2016 SR0473
Mifegymiso Mifepristone and misoprostol Medical termination of pregnancy Reimburse Complete October 7, 2016 April 18, 2017 SR0502
Monoferric Iron (III) Isomaltoside 1000 iron deficiency anemia Reimburse with clinical criteria and/or conditions Complete June 26, 2019 March 25, 2020 SR0622-000
Monoprost latanoprost glaucoma and ocular hypertension Reimburse with clinical criteria and/or conditions Complete October 25, 2017 April 24, 2018 SR0541-000
Movapo apomorphine hydrochloride Parkinson's disease Reimburse with clinical criteria and/or conditions Complete July 6, 2017 January 23, 2018 SR0527-000
Mozobil Plerixafor Hematopoietic stem cell mobilizer in non-Hodgkin's lymphoma and multiple myeloma Do not list Complete January 24, 2012 September 26, 2012 SR0265
Multaq Dronedarone hydrochloride Atrial fibrillation Do not list Complete September 18, 2009 May 27, 2010 S0177
Myfortic Mycophenolate sodium Organ rejection in allogeneic renal transplants, Prophylaxis List in a similar manner to other drugs in class Complete March 3, 2005 July 8, 2005 S0034
Myozyme Alglucosidase Pompe’s disease List with clinical criteria and/or conditions Complete October 10, 2006 June 14, 2007 S0080
Myrbetriq Mirabegron Bladder, overactive List with criteria/condition Complete November 27, 2013 November 12, 2014 SR0363
Myrbetriq Mirabegron Bladder, Overactive Withdrawn March 8, 2013 SR0319
Naglazyme Galsulfase (Drug Plan Submission) Mucopolysaccharidosis VI List with clinical criteria and/or conditions Complete August 20, 2015 February 19, 2016 SR0434-000
Nesina Alogliptin Diabetes mellitus (Type 2) Do not list Complete January 30, 2014 January 15, 2015 SR0368-000
Neulasta Pegfilgrastim Neutropenia List with clinical criteria and/or conditions Complete March 29, 2004 October 27, 2004 S0009
Neupro Rotigotine Parkinson’s Disease Do not list Complete July 31, 2013 May 28, 2014 SR0344
Neupro Rotigotine Parkinson’s Disease List with clinical criteria and/or conditions Complete May 21, 2015 November 19, 2015 SR0432-000
Nexavar Sorafenib tablets Cancer, Renal cell carcinoma Do not list Complete July 31, 2006 February 28, 2007 S0071
Nexplanon etonogestrel Prevention of pregnancy Reimburse with clinical criteria and/or conditions Active June 3, 2020 October 20, 2020 SR0648-000
Nitisinone nitisinone Hereditary tyrosinemia type 1 Reimburse with clinical criteria and/or conditions Complete January 25, 2018 August 23, 2018 SR0554-000
Norprolac Quinagolide hydrochloride Hyperprolactinemia List with clinical criteria and/or conditions Complete November 23, 2005 May 17, 2006 S0046
Norprolac Quinagolide hydrochloride Hyperprolactinemia Do not list Complete December 16, 2004 September 28, 2005 S0026
Nplate Romiplostim Chronic immune (idiopathic) thrombocytopenic purpura (ITP) Do not list Complete September 29, 2009 May 27, 2010 S0179
Nucala mepolizumab Asthma, severe eosinophilic Reimburse with clinical criteria and/or conditions Complete October 24, 2018 March 27, 2019 SF0593-000
Nucala Mepolizumab Asthma, severe eosinophilic Reimburse with clinical criteria and/or conditions Complete December 18, 2015 June 16, 2016 SR0461-000
Nucynta tapentadol hydrochloride pain, severe Do not reimburse Complete April 17, 2018 October 23, 2018 SR0563-000
NuvaRing Etonogestrel/ethinyl estradiol Contraceptive, ring List with clinical criteria and/or conditions Complete May 5, 2006 November 29, 2006 S0062
Ocaliva Obeticholic Acid Primary biliary cholangitis Reimburse with clinical criteria and/or conditions Complete December 22, 2016 July 25, 2017 SR0509-000
Ocrevus ocrelizumab multiple sclerosis, relapsing Reimburse with clinical criteria and/or conditions Complete May 16, 2017 November 21, 2017 SR0519-000
Ocrevus ocrelizumab Primary progressive multiple sclerosis Reimburse with clinical criteria and/or conditions Complete October 26, 2017 April 26, 2018 SR0542-000
Odefsey emtricitabine/rilpivirine/ tenofovir alafenamide HIV-1 infection Reimburse with clinical criteria and/or conditions Complete November 24, 2016 May 25, 2017 SR0507-000
Ofev nintedanib chronic fibrosing interstitial lung diseases Active July 24, 2020 SR0654-000
Ofev Nintedanib Idiopathic pulmonary fibrosis (IPF) List with clinical criteria and/or conditions Complete April 23, 2015 October 15, 2015 SR0426-000
Olmetec Olmesartan medoxomil Hypertension List in a similar manner to other drugs in class Complete November 28, 2008 May 27, 2009 S0150
Olmetec Plus Olmesartan medoxomil + hydrochlorothiazide Hypertension List in a similar manner to other drugs in class Complete November 28, 2008 May 27, 2009 S0151
Olumiant baricitinib Arthritis, Rheumatoid Reimburse with clinical criteria and/or conditions Complete December 20, 2018 August 2, 2019 SR0597-000
Omnaris Ciclesonide nasal spray Allergic Rhinitis (seasonal and perennial) Do not list Complete May 7, 2008 November 12, 2008 S0137
Omnitrope Somatropin (rDNA origin) Growth hormone deficiency in children and adults Complete June 12, 2009 S0167
Onbrez Indacaterol Chronic Obstructive Pulmonary Disease (COPD), maintenance bronchodilator treatment List in a similar manner Complete February 29, 2012 August 16, 2012 SR0273
Onglyza Saxagliptin Diabetes mellitus (Type 2) List with criteria/condition Complete May 9, 2013 November 15, 2013 SR0329
Onglyza Saxagliptin Diabetes mellitus (Type 2) Do not list Complete November 9, 2009 June 17, 2010 S0185
Onglyza Saxagliptin Diabetes mellitus (Type 2) Withdrawn May 28, 2012 SR0280
Onpattro patisiran Polyneuropathy in hereditary transthyretin-mediated amyloidosis Reimburse with clinical criteria and/or conditions Complete January 25, 2019 July 25, 2019 SR0598-000
Onsolis Fentanyl Citrate Pain (breakthrough), cancer (adults) Withdrawn May 10, 2011 S0229
Onsolis Fentanyl Citrate Pain (breakthrough), cancer (adults) Do not list Complete August 22, 2011 February 15, 2012 S0248
Onstryv safinamide Parkinson's disease Do not reimburse Complete May 29, 2019 March 25, 2020 SR0617-000
Opdivo-Yervoy Nivolumab-Ipilimumab ​OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. Received October 29, 2020 PC0229-000
Opsumit Macitentan Pulmonary arterial hypertension List with clinical criteria and/or conditions Complete December 18, 2015 January 28, 2015 SR0364
Oralair Grass Pollen Allergen Extract Allergic rhinitis (grass pollen) List with criteria/condition Complete September 21, 2012 March 20, 2013 SR0290
Orencia Abatacept Arthritis, Rheumatoid List with clinical criteria and/or conditions Complete October 26, 2006 June 27, 2007 S0084
Orencia Abatacept Arthritis, Rheumatoid List with clinical criteria and/or conditions Complete November 29, 2012 July 18, 2013 SR0299
Orencia Abatacept Arthritis, Rheumatoid List in a similar manner Complete December 2, 2009 June 17, 2010 S0187
Orencia Abatacept Arthritis, Juvenile Idiopathic & Juvenile Rheumatoid List with clinical criteria and/or conditions Complete August 29, 2008 April 22, 2009 S0145
Orfadin nitisinone Hereditary tyrosinemia type 1 Reimburse with clinical criteria and/or conditions Complete August 29, 2017 February 21, 2018 SR0531-000
Orilissa elagolix Moderate to severe pain associated with endometriosis CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer NotFiled
Orkambi lumacaftor/ivacaftor Cystic Fibrosis, F508del CFTR mutation Do not reimburse Complete January 28, 2016 October 26, 2016 SR0471-000
Orkambi lumacaftor/ivacaftor Cystic Fibrosis, F508del CFTR mutation in patients 6 years and older Do not reimburse Complete February 22, 2018 September 26, 2018 SR0559-000
Otezla Apremilast Psoriasis, moderate to severe plaque Do not list Complete October 8, 2014 July 22, 2015 SR0400-000
Otezla Apremilast Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Complete March 3, 2016 October 26, 2016 SR0478-000
Otezla Apremilast Arthritis, psoriatic List with criteria/condition Complete June 8, 2015 December 17, 2015 SR0437-000
Ozanex ozenoxacin Impetigo Do not reimburse Complete January 25, 2018 October 24, 2018 SR0553-000
Ozempic semaglutide Diabetes mellitus, type 2 Reimburse with clinical criteria and/or conditions Complete November 23, 2018 May 15, 2019 SR0594-000
Ozurdex Dexamethasone intravitreal implant Macular edema following central retinal vein occlusion Do not list Complete September 1, 2011 April 25, 2012 S0247
Ozurdex dexamethasone Diabetic macular edema Do not reimburse Complete September 26, 2017 October 24, 2018 SR0535-000
Pegasys RBV Peginterferon alfa-2a and Ribavirin Hepatitis C, chronic List in a similar manner to other drugs in class Complete May 14, 2004 October 14, 2004 S0013
Pheburane Sodium phenylbutyrate Urea cycle disorders List Complete October 20, 2015 April 15, 2016 SR0452-000
Picato Ingenol mebutate Keratosis, actinic Do not list Complete May 9, 2013 January 22, 2014 SR0330
Picato Ingenol mebutate Actinic keratosis Complete May 26, 2014 SF0382-000
Pifeltro doravirine HIV-1 infection Reimburse with clinical criteria and/or conditions Complete November 16, 2018 May 14, 2019 SR0582-000
Plegridy Peginterferon beta-1a Multiple Sclerosis, relapsing List with criteria/condition Complete June 26, 2015 December 17, 2015 SR0440-000
Teveten Plus Eprosartan mesylate/ hydrochlorothiazide Hypertension, Essential List in a similar manner to other drugs in class Complete July 8, 2004 December 15, 2004 S0016
Pradaxa Dabigatran etexilate Atrial fibrillation prevention of stroke and systemic embolism List with clinical criteria and/or conditions Complete March 18, 2013 July 18, 2013 SF0320-000
Pradaxa Dabigatran etexilate Atrial fibrillation prevention of stroke and systemic embolism Cancelled May 31, 2010 S0202
Pradaxa Dabigatran etexilate Atrial fibrillation prevention of stroke and systemic embolism List with clinical criteria and/or conditions Complete October 28, 2010 June 22, 2011 S0214
Pradaxa Dabigatran etexilate Thromboembolism (venous), prevention Do not list Complete July 8, 2008 January 28, 2009 S0140
Praluent Alirocumab Primary hypercholesterolemia (non-familial and heterozygous familial), mixed dyslipidemia Reimburse with clinical criteria and/or conditions Complete January 12, 2016 July 20, 2016 SR0469-000
Praxbind Idarucizumab (Drug Plan Submission) Reversal of dabigatran anticoagulant effects Withdrawn May 30, 2016 SR0492-000
Prevymis letermovir Cytomegalovirus infection, prophylaxis Reimburse with clinical criteria and/or conditions Complete December 7, 2017 June 20, 2018 SR0545-000
Prexige Lumiracoxib Osteoarthritis (Knee) Do not list Complete December 15, 2006 July 25, 2007 S0090
Prezcobix Darunavir/cobicistat HIV Infection List with criteria/condition Complete May 22, 2014 March 18, 2015 SR0381-000
Prezista Darunavir HIV infection List with clinical criteria and/or conditions Complete August 29, 2006 February 14, 2007 S0072
Prezista Darunavir HIV (treatment naive) List with clinical criteria and/or conditions Complete March 27, 2009 October 14, 2009 S0163
Prezista Darunavir HIV infection (Pediatric) List with clinical criteria and/or conditions Complete December 22, 2009 June 17, 2010 S0194
Pristiq Desvenlafaxine succinate Depressive, Major Disorder (MDD) Do not list Complete March 5, 2009 September 23, 2009 S0159
Probuphine buprenorphine hydrochloride Opioid drug dependence, treatment Reimburse with clinical criteria and/or conditions Complete December 21, 2017 August 22, 2018 SR0550-000
Procysbi cysteamine bitartrate Nephropathic cystinosis Reimburse with clinical criteria and/or conditions Complete August 8, 2017 January 24, 2018 SR0526-000
Prolia Denosumab Osteoporosis, postmenopausal women List with clinical criteria and/or conditions Complete August 26, 2010 March 30, 2011 S0208
Prolia Denosumab Osteoporosis, postmenopausal women Reimburse with clinical criteria and/or conditions Complete October 26, 2015 May 20, 2016 SF0453-000
Prolia Denosumab (Drug Plan Submission) Osteoporosis, men List with clinical criteria and/or conditions Complete March 10, 2015 September 21, 2015 SR0414-000
Quinsair Levofloxacin Cystic fibrosis with chronic pulmonary Pseudomonas aeruginosa infections Reimburse with clinical criteria and/or conditions Complete May 31, 2016 November 21, 2016 SR0493-000
Radicava edaravone amyotrophic lateral sclerosis Reimburse with clinical criteria and/or conditions Complete July 5, 2018 March 27, 2019 SR0573-000
Ralivia Tramadol hydrochloride Pain Do not list Complete October 29, 2007 June 25, 2008 S0110
RAPAFLO Silodosin Prostatic Hyperplasia, benign Do not list Complete October 25, 2011 April 19, 2012 S0261
Raptiva Efalizumab Psoriasis, moderate to severe chronic plaque List with clinical criteria and/or conditions Complete October 25, 2005 August 24, 2006 S0043
Raptiva Efalizumab Psoriasis, moderate to severe chronic plaque Complete June 19, 2007 S0102
Rasilez Aliskiren Hypertension Do not list Complete November 30, 2007 June 25, 2008 S0118
Ravicti glycerol phenylbutyrate Urea cycle disorders Reimburse with clinical criteria and/or conditions Complete August 30, 2016 March 21, 2017 SR0497-000
Rebif Interferon beta-1a Clinically Isolated Syndrome Do not list Complete March 8, 2013 August 15, 2013 SR0298
Reblozyl luspatercept Reblozyl® (luspatercept for injection) is indicated for the treatment of adult patients with red blood cell (RBC) transfusion-dependent anemia associated with beta(β)-thalassemia Pending SR0669-000
Relistor Methylnaltrexone bromide Constipation, Opioid-induced Do not list Complete May 7, 2008 January 28, 2009 S0135
Relpax Eletriptan hydrobromide Migraine Do not list Complete September 21, 2004 March 23, 2005 S0021
Remicade Infliximab Ulcerative Colitis Do not list Complete September 29, 2008 April 22, 2009 S0146
Remodulin Treprostinil sodium Pulmonary arterial hypertension (NYHA Class III and IV patients) List with clinical criteria and/or conditions Complete February 24, 2006 July 20, 2006 S0052
Remodulin Treprostinil sodium Pulmonary arterial hypertension (NYHA Class III and IV patients) Do not list Complete July 14, 2004 November 17, 2004 S0011
Remsima Infliximab Ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis Withdrawn May 30, 2014 SE0383-000
Renflexis infliximab rheumatoid arthritis, ankylosing spondylitis, adult Crohn’s disease, pediatric Crohn’s disease, fistulising Crohn’s disease, adult ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis, plaque psoriasis Reimburse with clinical criteria and/or conditions Complete September 5, 2017 February 20, 2018 SE0532-000
Repatha Evolocumab Primary hyperlipidemia and mixed dyslipidemia List with clinical criteria and/or conditions Complete June 30, 2015 February 19, 2016 SR0441-000
Repatha Evolocumab Primary hyperlipidemia and mixed dyslipidemia Reimburse with clinical criteria and/or conditions Complete February 17, 2017 November 22, 2017 SR0515-000
Replagal Agalsidase alfa Fabry Disease Do not list Complete February 19, 2004 November 24, 2004 S0006
Resotran Prucalopride Constipation, chronic Do not list Complete January 30, 2012 July 19, 2012 SR0266
Spiriva Respimat Tiotropium bromide Chronic Obstructive Pulmonary Disease (COPD) List with clinical criteria and/or conditions Complete December 23, 2014 July 16, 2015 SR0412-000
Revatio Sildenafil citrate Pulmonary arterial hypertension (WHO class II and III) List in a similar manner Complete September 20, 2006 February 14, 2007 S0076
Revestive teduglutide Short Bowel Syndrome (SBS), pediatrics Reimburse with clinical criteria and/or conditions Complete May 29, 2019 November 19, 2019 SR0606-000
Revestive Teduglutide Short Bowel Syndrome (SBS) Reimburse with clinical criteria and/or conditions Complete November 26, 2015 July 27, 2016 SR0459-000
Revolade Eltrombopag olamine Thrombocytopenic purpura chronic immune (idiopathic) Do not list Complete April 26, 2011 October 24, 2011 S0230
Revolade eltrombopag Severe aplastic anemia CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer NotFiled
Revolade Eltrombopag Thrombocytopenia associated with chronic hepatitis c infection List with criteria/condition Complete March 31, 2014 March 18, 2015 SR0377
Rexulti Brexpiprazole Schizophrenia Reimburse with clinical criteria and/or conditions Complete February 3, 2017 November 22, 2017 SR0514-000
Reyataz Atazanavir HIV infection List in a similar manner to other drugs in class Complete December 16, 2003 May 27, 2004 S0002
Rinvoq upadacitinib Arthritis, Rheumatoid Reimburse with clinical criteria and/or conditions Complete July 4, 2019 February 4, 2020 SR0614-000
Rituxan Rituximab Arthritis, Rheumatoid List with clinical criteria and/or conditions Complete June 26, 2006 February 14, 2007 S0068
Rituxan Rituximab Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA), remission induction (adults) List with clinical criteria and/or conditions Complete February 24, 2012 August 16, 2012 SR0270
Rosiver Ivermectin Rosacea List with criteria/condition Complete April 30, 2015 November 19, 2015 SR0429-000
Ruzurgi amifampridine Lambert-Eaton myasthenic syndrome Received October 5, 2020 SR0660-000
Rybelsus semaglutide As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus: as monotherapy when metformin is considered inappropriate due to intolerance or contraindications; in combination with other medicinal products for the treatment of diabetes Pending SR0637-000
Samsca Tolvaptan Hyponatremia, non-hypovolemic Do not list Complete July 3, 2012 February 13, 2013 SR0283
Saphris Asenapine Schizophrenia Do not list Complete December 12, 2011 June 14, 2012 S0262-000
Saphris Asenapine Bipolar I disorder List with clinical criteria and/or conditions Complete December 12, 2011 June 14, 2012 S0262-001
Sativex Delta-9-tetrahydrocannabinol/cannabidiol Pain, Neuropathic (adjunctive) in MS. Do not list Complete February 27, 2007 September 26, 2007 S0092
Sativex Delta-9-tetrahydrocannabinol/cannabidiol Pain, cancer (adjunctive analgesia to maximum tolerated strong opioids) Do not list Complete August 7, 2007 February 20, 2008 S0106
Sebivo Telbivudine Hepatitis B (chronic) Do not list Complete December 4, 2006 September 26, 2007 S0088
Seebri Glycopyrronium bromide Chronic Obstructive Pulmonary Disease (COPD), maintenance bronchodilator treatment List with criteria/condition Complete November 30, 2012 May 15, 2013 SR0300
Segluromet ertugliflozin and metformin hydrochloride Diabetes mellitus, Type 2 Do not reimburse Complete April 30, 2018 January 23, 2019 SR0566-000
Semglee insulin glargine Diabetes mellitus, Type 1 & 2 Withdrawn November 14, 2018 SE0589-000
Sensipar Cinacalcet hydrochloride Secondary hyper-parathyroidism in chronic kidney disease Do not list Complete August 20, 2004 March 23, 2005 S0018
Signifor Pasireotide diaspartate Cushing’s Disease Do not list Complete February 27, 2014 February 24, 2015 SR0372-000
Siliq brodalumab Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Complete December 14, 2017 June 20, 2018 SR0547-000
Silkis Calcitriol Psoriasis, mild to moderate plaque Do not list Complete March 15, 2010 September 22, 2010 S0199
Simbrinza Brinzolamide / brimonidine Glaucoma and ocular hypertension List Complete November 3, 2014 June 17, 2015 SR0403-000
Simponi Golimumab Arthritis, psoriatic List in a similar manner Complete September 3, 2009 March 17, 2010 S0195
Simponi Golimumab Ankylosing spondylitis List in a similar manner Complete September 3, 2009 March 17, 2010 S0196
Simponi Golimumab Ulcerative colitis Do not list at the submitted price Complete July 12, 2013 March 19, 2014 SR0341
Simponi Golimumab Arthritis, Rheumatoid List in a similar manner Complete September 3, 2009 March 17, 2010 S0174
Sivextro Tedizolid phosphate Acute bacterial skin and skin structure infections Withdrawn January 16, 2015 SR0413-000
Skyrizi risankizumab Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Complete October 22, 2018 May 28, 2019 SR0583-000
Soliqua lixisenatide + insulin glargine Diabetes mellitus, Type 2 Reimburse with clinical criteria and/or conditions Complete May 18, 2018 December 24, 2018 SR0564-000
Soliris Eculizumab Hemolytic Uremic Syndrome, Atypical Complete February 9, 2015 SF0416-000
Soliris Eculizumab Paroxysmal nocturnal hemoglobinuria (PNH) Do not list Complete September 18, 2009 February 18, 2010 S0176
Soliris eculizumab Neuromyelitis optica spectrum disorder Reimburse with clinical criteria and/or conditions Complete February 25, 2020 August 19, 2020 SR0640-000
Soliris eculizumab Myasthenia Gravis (gMG), adults Reimburse with clinical criteria and/or conditions Active April 1, 2020 October 19, 2020 SR0605-000
Soliris Eculizumab Hemolytic Uremic Syndrome, Atypical Do not list Complete January 7, 2013 July 18, 2013 SR0304
Somavert Pegvisomant acromegaly Do not list Complete January 25, 2006 August 2, 2006 S0050
Sovaldi Sofosbuvir Hepatitis C, chronic List with criteria/condition Complete October 1, 2013 August 18, 2014 SR0356
Sovaldi sofosbuvir Hepatitis C, chronic Reimburse with clinical criteria and/or conditions Complete January 6, 2016 May 18, 2016 SF0464-000
Spinraza nusinersen Spinal Muscular Atrophy Reimburse with clinical criteria and/or conditions Complete June 28, 2017 December 22, 2017 SR0525-000
Spinraza Nusinersen Spinal Muscular Atrophy Reimburse with clinical criteria and/or conditions Complete July 24, 2018 February 27, 2019 SR0576-000
Spravato esketamine hydrochloride Major depressive disorder (MDD), adults Active June 24, 2019 SR0621-000
Spriafil Posaconazole Aspergillus and Candida infections Do not list Complete May 24, 2007 January 30, 2008 S0097
Stalevo Carbidopa, levodopa and entacapone Parkinsons Disease List in a similar manner Complete April 15, 2008 October 16, 2008 S0131
Steglatro ertugliflozin Diabetes mellitus, Type 2 Do not reimburse Complete April 30, 2018 January 23, 2019 SR0565-000
Stelara Ustekinumab Psoriasis List with clinical criteria and/or conditions Complete January 7, 2009 June 17, 2009 S0156
Stelara Ustekinumab Arthritis, Psoriatic Do not list at the submitted price Complete October 30, 2013 October 20, 2014 SR0359-000
Strattera Atomoxetine hydrochloride Attention deficit hyperactivity disorder Do not list Complete January 25, 2005 September 28, 2005 S0031
Strattera Atomoxetine hydrochloride Attention deficit hyperactivity disorder Complete September 25, 2006 S0085
Strensiq Asfotase alfa Hypophosphatasia, pediatric-onset List with criteria/condition Complete August 21, 2015 March 23, 2016 SR0443-000
Stribild Elvitegravir/ Cobicistat/ Emtricitabine/ Tenofovir Disoproxil Fumarate HIV-1 infection List with criteria/condition Complete November 30, 2012 May 15, 2013 SR0301
Sublinox Zolpidem tartrate Insomnia, short-term treatment Do not list Complete March 7, 2013 September 25, 2013 SR0314
Sublocade buprenorphine Opioid use disorder, treatment Reimburse with clinical criteria and/or conditions Complete December 20, 2018 June 19, 2019 SR0579-000
Suboxone Buprenorphine/naloxone Opioid drug dependence (Substitution treatment) List with clinical criteria and/or conditions Complete March 6, 2008 September 24, 2008 S0128
Sunvepra Asunaprevir Hepatitis C, chronic Reimburse with clinical criteria and/or conditions Complete February 13, 2015 July 20, 2016 SR0418-000
Sutent Sunitinib Gastrointestinal stromal tumour (GIST) List with clinical criteria and/or conditions Complete July 20, 2006 March 28, 2007 S0069
Sutent Sunitinib malate Cancer, Metastatic renal cell carcinoma Do not list Complete September 20, 2006 April 26, 2007 S0077
Symdeko tezacaftor/ivacaftor Cystic fibrosis, F508del mutation(s) CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer NotFiled
Symtuza Darunavir/cobicistat/emtricitabine/tenofovir alafenamide HIV-1 infection Reimburse with clinical criteria and/or conditions Complete December 22, 2017 July 25, 2018 SR0552-000
Synjardy Empagliflozin and metformin Diabetes mellitus (Type 2) Reimburse with clinical criteria and/or conditions Complete April 29, 2016 October 25, 2016 SR0489-000
Takhzyro lanadelumab Hereditary angioedema, prevention Reimburse with clinical criteria and/or conditions Complete May 29, 2019 November 19, 2019 SR0618-000
Taltz ixekizumab Ankylosing spondylitis Reimburse with clinical criteria and/or conditions Complete September 20, 2019 March 24, 2020 SR0630-000
Taltz Ixekizumab Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Complete March 23, 2016 October 25, 2016 SR0481-000
Taltz ixekizumab Arthritis, psoriatic Reimburse with clinical criteria and/or conditions Complete February 20, 2018 August 21, 2018 SR0558-000
Tarceva Erlotinib Cancer, Lung , non-small cell List with clinical criteria and/or conditions Complete July 19, 2005 December 7, 2005 S0037
Targin Oxycodone / naloxone Pain, Moderate to severe and relief of opioid-induced constipation Cancelled November 30, 2010 S0219
Targin Oxycodone HCI / naloxone HCI Pain, Moderate to severe and relief of opioid-induced constipation Do not list Complete July 5, 2011 January 25, 2012 S0241
TBC Darunavir / cobicistat HIV infection Withdrawn April 4, 2014 SR0378-000
TBC risdiplam Spinal muscular atrophy Pending SR0661-000
TBC filgotinib Arthritis, Rheumatoid Received SR0656-000
TBC filgrastim Prevention or treatment of neutropenia in various indications Cancelled November 1, 2018 SE0585-000
TBC etonogestrel Prevention of pregnancy Withdrawn September 26, 2019 SR0629-000
TBC filgrastim neutropenia, blood cell mobilization (various indications) Cancelled SE0596-000
TBC ranolazine Stable angina pectoris, adults Active August 17, 2020 SR0655-000
TBC infliximab Rheumatoid arthritis, Crohn’s disease, ulcerative colitis Active September 24, 2020 SR0659-000
TBC ravulizumab Paroxysmal nocturnal hemoglobinuria. Suspended July 4, 2019 SR0623-000
TBC halobetasol propionate and tazarotene Psoriasis, moderate to severe plaque Withdrawn February 4, 2019 SR0600-000
TBC ofatumumab Multiple Sclerosis, relapsing Active August 25, 2020 SR0657-0000
Tecfidera Dimethyl fumarate Multiple Sclerosis, relapsing List with criteria/condition Complete February 4, 2013 September 25, 2013 SR0309
Technivie Ombitasvir/ paritaprevir/ ritonavir Hepatitis C, chronic (genotype 4) List with clinical criteria and/or conditions Complete September 4, 2015 March 18, 2016 SR0444-000
Tegsedi inotersen hereditary transthyretin amyloidosis Reimburse with clinical criteria and/or conditions Complete February 22, 2019 December 18, 2019 SR0603-000
Telzir Fosamprenavir calcium HIV infection List in a similar manner to other drugs in class Complete January 24, 2005 June 16, 2005 S0030
Thelin Sitaxsentan sodium Pulmonary arterial hypertension (WHO class II and III) Do not list Complete May 5, 2008 January 28, 2009 S0132
Thelin Sitaxsentan sodium Pulmonary arterial hypertension (WHO class II and III) Do not list Complete June 22, 2007 January 30, 2008 S0099
Tivicay Dolutegravir HIV infection List Complete October 18, 2013 August 18, 2014 SR0357
Toctino Alitretinoin Eczema List with clinical criteria and/or conditions Complete May 6, 2011 October 24, 2011 S0232
Toviaz Fesoterodine fumarate Bladder, overactive List in a similar manner Complete April 27, 2012 October 18, 2012 SR0277
Trajenta Linagliptin Diabetes mellitus, Type 2 List with clinical criteria and/or conditions Complete August 23, 2011 February 15, 2012 S0244
Tramacet Tramadol hydrochloride /acetaminophen Acute pain Do not list Complete October 2, 2006 May 17, 2007 S0079
Translarna ataluren Dystrophinopathy Cancelled SR0607-000
Trelstar Triptorelin pamoate Cancer, prostate List in a similar manner to other drugs in class Complete February 27, 2006 July 20, 2006 S0051
Tremfya guselkumab Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Complete August 25, 2017 February 21, 2018 SR0530-000
Tresiba insulin degludec Diabetes mellitus, Type 1 & 2 Reimburse with clinical criteria and/or conditions Complete May 31, 2017 November 20, 2017 SR0521-000
Tridural Tramadol hydrochloride Pain Do not list Complete November 29, 2007 April 17, 2008 S0117
Trintellix vortioxetine hydrobromide Major depressive disorder (MDD), adults. Reimburse with clinical criteria and/or conditions Complete May 1, 2019 February 12, 2020 SR0611-000
Trintellix Vortioxetine Depression, Major Depressive Disorder (MDD) Withdrawn October 31, 2014 SR0402-000
Triumeq Dolutegravir / abacavir / lamivudine HIV Infection List with criteria/condition Complete July 31, 2014 April 17, 2015 SR0387
Trosec Trospium chloride Bladder, overactive List with clinical criteria and/or conditions Complete March 24, 2006 August 24, 2006 S0055
Trulicity Dulaglutide Diabetes mellitus, Type 2 Reimburse with clinical criteria and/or conditions Complete December 22, 2015 June 16, 2016 SR0462-000
Truvada Emtricitabine/tenofovir disoproxil fumarate HIV infection List with clinical criteria and/or conditions Complete May 29, 2006 October 25, 2006 S0063
Truvada Emtricitabine/tenofovir disoproxil fumarate HIV infection List with clinical criteria and/or conditions Complete July 7, 2008 December 17, 2008 S0138
Truvada Emtricitabine/tenofovir disoproxil fumarate HIV-1 infection, pre-exposure prophylaxis Reimburse with clinical criteria and/or conditions Complete March 3, 2016 August 24, 2016 SR0479-000
Twynsta Telmisartan/ Amlodipine Hypertension, Essential List Complete August 23, 2011 December 16, 2011 S0245
Twynsta Telmisartan / Amlodipine Hypertension, Essential Cancelled July 9, 2010 S0207
Tysabri Natalizumab Multiple Sclerosis, relapsing-remitting List with clinical criteria and/or conditions Complete May 6, 2008 February 25, 2009 S0133
Tysabri Natalizumab Multiple Sclerosis, relapsing-remitting Do not list Complete October 26, 2006 April 26, 2007 S0082
Uloric Febuxostat Gout List with clinical criteria and/or conditions Complete October 27, 2010 April 25, 2011 S0213
Uptravi Selexipag Pulmonary arterial hypertension (WHO class II and III) Reimburse with clinical criteria and/or conditions Complete March 31, 2016 October 28, 2016 SR0482-000
Vantas Histrelin acetate Cancer, prostate Do not list Complete September 20, 2006 April 26, 2007 S0078
Vascepa icosapent ethyl Ischemic events in statin-treated patients Reimburse with clinical criteria and/or conditions Complete June 17, 2019 July 16, 2020 SR0619-000
Velphoro sucroferric oxyhydroxide Hyperphosphatemia, end-stage renal disease Reimburse with clinical criteria and/or conditions Complete June 12, 2018 January 2, 2019 SR0571-000
Veltassa patiromer Hyperkalemia, adults (chronic kidney disease) Pending SR0665-000
Vemlidy tenofovir alafenamide Hepatitis B, chronic Reimburse with clinical criteria and/or conditions Complete September 28, 2017 March 26, 2018 SR0537-000
Verkazia cyclosporine Severe vernal keratoconjunctivitis, pediatric (≥4 years) Reimburse with clinical criteria and/or conditions Complete May 22, 2019 November 18, 2019 SR0615-000
Vesicare Solifenacin succinate Bladder, overactive List with clinical criteria and/or conditions Complete January 5, 2009 June 17, 2009 S0155
Vesicare Solifenacin succinate Bladder, overactive Do not list Complete July 24, 2006 January 24, 2007 S0070
VesiFlow Solifenacin succinate / tamsulosin hydrochloride Benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms Withdrawn April 6, 2015 SR0424-000
VFEND Voriconazole Candidemia List with clinical criteria and/or conditions Complete March 24, 2006 October 25, 2006 S0056
VFEND Voriconazole Aspergillosis, Invasive List with clinical criteria and/or conditions Complete October 25, 2004 April 14, 2005 S0023
VFEND Voriconazole Aspergillosis, Invasive Withdrawn August 24, 2004 S0020
Viacoram perindopril arginine / amlodipine Hypertension, essential Reimburse with clinical criteria and/or conditions Complete May 2, 2016 October 26, 2016 SR0490-000
Viberzi eluxadoline Irritable bowel syndrome with diarrhea Do not reimburse Complete February 23, 2018 August 24, 2018 SR0560-000
Victoza Liraglutide Diabetes mellitus, Type 2 Do not list Complete November 29, 2010 September 28, 2011 S0217
Victoza Liraglutide Diabetes Mellitus, Type 2 Withdrawn October 20, 2016 SR0505-000
Victrelis Boceprevir Hepatitis C, chronic List with criteria/condition Complete December 21, 2012 June 13, 2013 SF0303
Victrelis Boceprevir Hepatitis C infection, chronic List with criteria/condition Complete February 19, 2013 June 13, 2013 SF0312
Victrelis Boceprevir Hepatitis C, chronic List with clinical criteria and/or conditions Complete May 3, 2011 October 24, 2011 S0231
Viibryd vilazodone Depression, Major depressive disorder CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer NotFiled
Vimizim Elosulfase alfa Mucopolysaccharidosis IVA (Morquio A syndrome) Do not list Complete August 5, 2014 March 25, 2015 SR0389
Vimizim Elosulfase alfa Mucopolysaccharidosis IVA (Morquio A syndrome) Reimburse with clinical criteria and/or conditions Complete November 10, 2015 May 20, 2016 SR0456-000
Vimpat Lacosamide Epilepsy, partial onset seizures (POS) List with clinical criteria and/or conditions Complete October 25, 2010 April 25, 2011 S0212
Viread Tenofovir disoproxil fumarate HIV infection Complete July 7, 2008 S0139
Viread Tenofovir disoproxil fumarate Hepatitis B (chronic) List with clinical criteria and/or conditions Complete October 2, 2008 March 18, 2009 S0148
Viread Tenofovir disoproxil fumarate HIV infection Do not list Complete February 23, 2004 August 25, 2004 S0008
Viread Tenofovir disoproxil fumarate HIV infection List with clinical criteria and/or conditions Complete August 11, 2005 March 15, 2006 S0040
Visanne Dienogest Pain (pelvic) associated with endometriosis List with clinical criteria and/or conditions Complete October 18, 2011 April 19, 2012 S0255
Volibris Ambrisentan Pulmonary arterial hypertension (WHO class II and III) List with clinical criteria and/or conditions Complete July 9, 2008 December 17, 2008 S0142
Vonvendi von Willebrand Factor [recombinant] von Willebrand disease, adults, treatment and perioperative management Active April 29, 2020 ST0639-000
Vosevi sofosbuvir velpatasvir voxilaprevir Hepatitis C, chronic Reimburse with clinical criteria and/or conditions Complete July 28, 2017 January 23, 2018 SR0529-000
VPRIV Velaglucerase alfa Gaucher Disease List with clinical criteria and/or conditions Complete October 28, 2010 April 25, 2011 S0215
Vyndaqel tafamidis transthyretin-mediated amyloidosis Reimburse with clinical criteria and/or conditions Complete July 4, 2019 February 19, 2020 SR0625-000
Vyvanse Lisdexamfetamine dimesylate Attention deficit hyperactivity disorder Do not list Complete July 10, 2009 December 18, 2009 S0171
Vyzulta latanoprostene bunod Open-angle glaucoma or ocular hypertension Reimburse with clinical criteria and/or conditions Complete November 23, 2018 July 24, 2019 SR0590-000
Xarelto Rivaroxaban Thromboembolism (venous), prevention List with clinical criteria and/or conditions Complete May 7, 2008 December 17, 2008 S0134
Xarelto Rivaroxaban Thromboembolism (venous) prevention Complete June 24, 2011 S0239
Xarelto Rivaroxaban Deep-Vein Thrombosis (treatment), without Symptomatic Pulmonary Embolism Complete October 10, 2012 SF0295
Xarelto rivaroxaban Prevention of stroke and cardiovascular events in coronary and peripheral artery disease. Reimburse with clinical criteria and/or conditions Complete May 24, 2018 November 20, 2018 SR0569-000
Xarelto Rivaroxaban stroke prevention in patients with atrial fibrillation. List with clinical criteria and/or conditions Complete March 18, 2013 July 18, 2013 SF0321-00
Xarelto Rivaroxaban Thromboembolic events (venous), pulmonary embolism List with criteria/condition Complete May 6, 2013 March 26, 2014 SR0327
Xarelto Rivaroxaban Atrial fibrillation, stroke prevention List with clinical criteria and/or conditions Complete October 21, 2011 April 19, 2012 S0257
Xarelto Rivaroxaban Deep-Vein Thrombosis (treatment), without Symptomatic Pulmonary Embolism List with clinical criteria and/or conditions Complete February 27, 2012 August 16, 2012 SR0271
Xeljanz Tofacitinib Arthritis, Rheumatoid List with criteria/condition Complete May 5, 2014 April 17, 2015 SR0380-000
Xeljanz tofacitinib Ulcerative colitis Reimburse with clinical criteria and/or conditions Complete June 27, 2018 February 27, 2019 SR0572-000
Xeljanz tofacitinib Arthritis, Psoriatic Cancelled SR0575-000
Xeomin Clostridium botulinum neurotoxin type A, free from complexing proteins Blepharospasm List in a similar manner Complete June 12, 2009 December 16, 2009 S0168
Xeomin Clostridium botulinum neurotoxin type A, free from complexing proteins Cervical Dystonia List in a similar manner Complete June 12, 2009 December 16, 2009 S0192
Xeomin Clostridium botulinum neurotoxin type A, free from complexing proteins Spasticity, Post-stroke Do not list Complete June 12, 2009 December 16, 2009 S0193
Xermelo telotristat carcinoid syndrome Do not reimburse Complete September 27, 2018 June 26, 2019 SR0580-000
Xgeva Denosumab (Drug Plan Submission) Prevention of skeletal-related events due to bone metastases from breast cancer List with clinical criteria and/or conditions Complete July 31, 2015 February 25, 2016 SR0433-000
Xgeva Denosumab (Drug Plan Submission) Prevention of skeletal-related events due to bone metastases from other solid tumors (excluding breast and prostate cancer), including non-small cell lung cancer List with clinical criteria and/or conditions Complete July 31, 2015 March 23, 2016 SR0433-001
XGEVA Denosumab Prevention of skeletal-related events due to bone metastases from solid tumours List with clinical criteria and/or conditions Complete June 6, 2011 November 16, 2011 S0235
Xiaflex Collagenase clostridium histolyticum Dupuytren’s contracture with a palpable cord List with criteria/condition Complete August 30, 2012 March 27, 2013 SR0287
XigDuo dapagliflozin/metformin hydrochloride Diabetes Mellitus, Type 2 Reimburse with clinical criteria and/or conditions Complete January 7, 2016 July 20, 2016 SR0468-000
Zytram XL Tramadol hydrochloride Pain, acute Withdrawn November 3, 2006 S0086
Zytram XL Tramadol hydrochloride Pain, acute Do not list Complete March 15, 2007 September 26, 2007 S0093
Xolair Omalizumab Urticaria, chronic idiopathic List with clinical criteria and/or conditions Complete September 22, 2014 May 7, 2015 SR0398-000
Xolair Omalizumab Asthma, severe persistent Cancelled April 18, 2005 S0035
Xolair Omalizumab (Drug Plan Submission) Asthma, severe persistent Reimburse with clinical criteria and/or conditions Complete November 18, 2015 May 18, 2016 SR0457-000
Xolair Omalizumab Asthma, severe persistent Do not list Complete October 13, 2005 March 7, 2006 S0045
Xultophy insulin degludec + liraglutide Diabetes mellitus, Type 2 Reimburse with clinical criteria and/or conditions Complete January 30, 2019 October 24, 2019 SR0599-000
Xyrem Sodium oxybate Narcolepsy Do not list Complete July 9, 2008 January 28, 2009 S0141
Xyrem Sodium oxybate Narcolepsy Withdrawn August 29, 2007 S0107
Yasmin Drospirenone /ethinyl estradiol Contraceptive, oral List Complete January 20, 2005 June 16, 2005 S0029
Zavesca Miglustat Gaucher disease Do not list Complete May 13, 2004 November 24, 2004 S0012
Zaxine Rifaximin Encephalopathy, Hepatic List with criteria/condition Complete August 5, 2014 April 16, 2015 SR0388
Zeldox Ziprasidone hydrochloride Schizophrenia and related psychotic disorders List with clinical criteria and/or conditions Complete January 10, 2008 August 14, 2008 S0124
Zenhale Mometasone/formoterol Asthma maintenance (adults, children 12 or older) List with clinical criteria and/or conditions Complete June 6, 2012 December 19, 2012 S0281
Zepatier Elbasvir/grazoprevir Hepatitis C, chronic Reimburse with clinical criteria and/or conditions Complete October 27, 2015 May 19, 2016 SR0454-000
Zeposia ozanimod Multiple Sclerosis, relapsing - remitting Active August 25, 2020 SR0652-000
Zinbryta Daclizumab beta Multiple Sclerosis, relapsing Reimburse with clinical criteria and/or conditions Complete December 20, 2016 June 20, 2017 SR0508-000
Zolgensma onasemnogene abeparvovec Spinal muscular atrophy (SMA), pediatrics Active June 25, 2020 SG0649-000